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ABSTRACT 
 
The focus of these studies has been toward the development of new synthetic methods 
and procedures for the synthesis of novel compounds with unique biological properties. This 
research has led to the development of two new synthetic strategies for the construction of two 
novel amphibian alkaloids. In addition, the efforts have led to the large-scale process for the 
preparation of a novel analgesic compound. 
 
The regioselective ring opening of lactones (δ-valerolactone and γ-butyrolactone) with 
aryllithium reagents is reported for the construction of a series of δ-hydroxyarylketones and 
γ-hydroxyarylketones. 
 
Both the R and S enantiomers of the amphibian alkaloid noranabasamine were prepared 
in >30% overall yield with 80% ee and 86% ee, respectively. An enantioselective 
iridium-catalyzed N-heterocyclization reaction with either (R)- or (S)-1-phenylethylamine and 
1-(5-methoxypyridin-3-yl)-1,5-pentanediol was employed to generate the 
2-(pyridin-3-yl)-piperidine ring system in 69-72% yield. 
 
A cis-2,5-disubstitued pyrrolidine building block derived from (-)-Cocaine•HCl was 
prepared. We utilized this compound as a chiral building block for the formal synthesis of 
(+)-gephyrotoxin. Using this pyrrolidine building block, Kishi’s intermediate was obtained 
 xii
enantiospecifically in 15 steps and 9.4% overall yield. 
 
A large-scale process for the preparation of the analgesic compounds SCP-123 and its 
sodium salt, SCP-123ss•monohydrate has been developed. The process for the preparation of 
SCP-123 required three synthetic steps with no chromatography, while the process for the 
preparation of SCP-123ss required four synthetic steps and no           
chromatography. The overall yields for both SCP-123 and SCP-123ss were 47% and 46%, 
respectively, and both compounds were obtained in exceptionally high purity (>99%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: ketones, lactones, nucleophilic addition, ring-opening, enantioselective, 
noranabasamine, N-heterocyclization, gephyrotoxin, pyrrolidine, Kishi’s intermediate, analgesic, 
acetaminophen, propacetamol, saccharin, hydrolysis, parenteral administration. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
1.1. Nicotinic acetylcholine receptors 
 
Nicotinic acetylcholine receptors (nAChRs) are cholinergic receptors. Cholinergic 
receptors form ionotropic channels (i.e. ligand-gated) in the cell membranes of certain neurons. 
As ligand-gated ion channel receptors, nAChRs are connected to an ion channel directly; but 
they don’t employ a second messenger like metabotropic receptors.1 
 
Figure 1.1. Structure of (S)-nicotine and acetylcholine 
 
N
N
CH3
O
N
O
(S)-Nicotine 1 Acetylcholine 2  
 
Muscarinic acetylcholine receptors (mAChRs) are acetylcholine receptors as well. Both 
nAChR and mAChR are triggered by the binding of the neurotransmitter acetylcholine (ACh). 
However, nicotinic receptors are also activated by nicotine. Likewise, muscarinic receptors are 
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also opened by muscarine.1-3 Nicotinic acetylcholine receptors can be found in many tissues in 
the body, and are present in the peripheral nervous system (PNS) and the central nervous system 
(CNS). 
Although the nAChR has been cloned, the full mechanism by which these receptors 
function is still unclear. However, despite the lack of a definitive pharmacophore, nAChRs are 
attractive pharmacological targets for medication development for the treatment of a variety of 
disorders and disease states. 
 
1.2. Nicotinic acetylcholine receptor structure and receptor subtypes 
 
Nicotinic receptors have a molecular mass of 290 kDa4. A central pore is surrounded by 
five subunits symmetrically (Figure 1.2).5,6 The nAChRs are ligand-gated ion channels. The 
structures are composed with five (α or β or γ) subunits. The subunit can be homomeric (i.e. all α) 
or heteromeric (i.e. a mixture of α and β, Figure 1.2). 
One subunit of the nAChR comprises an N-terminal extracellular domain, four 
hydrophobic transmembrane domains (in dark blue), a long cytoplasmic loop and other shorter 
loops. The N-terminal extracellular domain is involved in the binding of (neurotransmitter) 
ligands. Four hydrophobic transmembrane domains (in dark blue) are named M1, M2, M3 and 
M4. The long cytoplasmic loop is connected to the M3 and M4 domains. The other shorter loops 
are between the other domains. 
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Figure 1.2. Structure of a neuronal nicotinic acetylcholine receptor (nAChR)7 
 
 
 
As seen in a cross-section (Figure 1.2), each subunit has a gate region and a 
neurotransmitter binding site. As a ligand-gated ion channel, it binds a specific neurotransmitter 
[in this case, nicotine (1)]. The binding process changes the conformation of the receptor ending 
with opening of the channel. The channel pore is lined with charged amino acids. These amino 
acids selectively transfer the ions through cell membrane and into the cell. Compared to all the 
other ionotropic receptors (GABAA receptors, glycine receptors and the 5HT 3 serotonin 
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receptors), or the signature Cys-loop proteins, they all have similar properties.8 
Based on the nicotinic receptor primary sites of expression, they are generally divided to 
two subtypes. The two subtypes are muscle type and neuronal type. The muscle type receptors 
are found at the neuromuscular junction. These receptors have two different forms. One is the 
embryonic form which is made up of α1, β1, δ, and γ subunits with a 2:1:1:1 ratio; The other is 
the adult form which is made up of α1, β1, δ, and ε subunits in a 2:1:1:1 ratio.1-3,9 The neuronal 
subtypes are combinations of twelve different nicotinic receptor subunits: α2 through α10 and β2 
through β4. The combinations are either homomeric or heteromeric. Several examples of the 
neuronal subtypes include (α4)3(β2)2, (α4)2(β2)3, and (α7)5. In the hydrophobic regions, all the 
subunits are the same, no matter whether it is a neuronal type receptor or a muscle type receptor.1  
 
1.3. Nicotinic acetylcholine receptor subunits 
 
There have been 17 nAChR subunits identified to date. All the subunits belong to either 
muscle type or neuronal type subunits. Among those 17 subunits, α2-α7 and β2-β4 can be cloned 
in human cells. All the other genes are present in chick and rat genomes.10 On the basis of similar 
protein sequence, the 17 nAChR subunits have been divided into 4 subfamilies (I-IV) (Table 
1.1).11 The subfamily III has been further divided into 3 types. 
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Table 1.1. Nicotinic acetylcholine receptor subunits 
 
Neuronal type Muscle type
I II III IV 
1 2 3 α9, α10 α7, α8 
α2, α3, α4, 
α6 
β2, β4 β3, α5 
α1, β1, δ, γ, 
ε 
 
1.4. Nicotinic acetylcholine receptor notable variations 
 
Each nicotinic receptor ion channel complex has five subunits to form the pentameric 
structure. So there are variety of combinations of these subunits. Among all the pentamers, 
several combinations are more prominent than others. For example, (α1)2β1δε (muscle type), 
(α3)2(β4)3 (ganglion type), (α4)2(β2)3 (CNS type) and (α7)5 (another CNS type) are shown in 
Table 1.2.12  
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Table 1.2. Comparison of notable nicotinic acetylcholine receptor 
 
Receptor 
type 
Location Effect Nicotinic 
agonists 
Antagonists 
Muscle type: 
(α1)2β1δε12 
or (α1)2β1δγ 
Neuromuscular 
junction 
EPSP, mainly 
by increased 
Na+ and K+ 
permeability 
acetylcholine1  
carbachol  
suxamethonium 
 
α-bungarotoxin  
α-conotoxin  
tubocurarine1  
pancuronium  
Ganglion 
type: 
(α3)2(β4)3 
autonomic 
ganglia 
EPSP, mainly 
by increased 
Na+ and K+ 
permeability 
acetylcholine1  
carbachol  
nicotine1  
epibatidine  
dimethylphenyl-
piperazinium  
varenicline  
α-bungarotoxin1  
mecamylamine  
trimetaphan  
hexamethonium  
bupropion  
dextromethorphan  
ibogaine  
18-methoxycoronaridine
CNS type: 
(α4)2(β2)3 
Brain Post- and 
presynaptic 
excitation,12 
mainly by 
increased Na+ 
and K+ 
permeability 
nicotine  
epibatidine  
acetylcholine  
cytisine  
 
mecamylamine  
methylcaconitine  
α-conotoxin  
 
(another) 
CNS type: 
(α7)5 
Brain Post- and 
presynaptic 
excitation,12 
mainly by 
increased Ca2+ 
permeability 
epibatidine  
dimethylphenyl-
piperazinium 
 
mecamylamine  
α-bungarotoxin1 
 
 
1.5. Nicotinic acetylcholine receptor binding the channel 
 
All ligand-gated ion channels are opened by an agonist chemical messenger binding to 
the nAChR. Acetylcholine is one of the endogenous agonists. There are other examples of 
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agonists of the nAChR including nicotine, epibatidine and choline. The binding site of 
acetylcholine is generated from the accumulation of amino acid residues. These residues are 
from both the α and β subunits. In the case of homomeric receptors, those residues will be 
between two α subunits near the N terminus in the extracellular domain.2 All present subunits 
will exhibit a conformational change when an agonist binds to the site. The channel then opens to 
generate a pore with a diameter of about 0.65 nm.2,13 
 
1.6. Nicotinic acetylcholine receptor opening the channel 
 
Nicotinic AChRs may have different conformational states that are interconvertible. With 
an agonist bound, the open process is stabilized and those states are desensitized. When the 
channel is open, positively charged ions can cross through the channel. Normally, Na+ enters the 
cell and K+ exits the cell. The net flow of ions with positive charge is inward. The nAChR is a 
cation channel with no selectivity. It means several ions with positive charge can move across the 
cell membrane.1 The ion channels are permeable to Na+ and K+ and the level of permeability 
depends upon combinations of the subunits. These subunits are also permeable to Ca2+.2 The 
amount of Na+ and K+ the channels can accommodate in their pores (their conductance) varies 
from 50-110 pS (picosiemens, 10–12 S). The conductance is also dependent upon the individual 
subunit composition as well as the permeant ion.14 
Interestingly, because Ca2+ can pass though some neuronal nAChRs, the release of other 
neurotransmitters can be affected at the same time.3 The channel normally opens rapidly and 
 8
closes when the agonist diffuses away. The whole process generally takes about 1 millisecond.2  
 
1.7. Nicotinic acetylcholine receptor effects 
 
The state of neurons is modified through the activation of receptors by nicotine. There are 
two main mechanisms during the process. First, the plasma membrane is depolarized by the 
movements of cations (an excitatory postsynaptic potential in neurons is generated in this case), 
and other voltage-gated ion channels are been activated as well. Second, when Ca+ moves along 
(directly or indirectly) the entrance, the action on different intracellular cascades will lead to the 
release of neurotransmitters or the regulation of some other gene activity. 
 
1.8. Nicotinic acetylcholine receptor regulation of desensitization 
 
Katz and Thesleff first characterized ligand-bound desensitization of receptors in the 
nicotinic acetylcholine receptor.15 The responsiveness of a receptor toward a stimulus generally 
decreased after prolonged or repeated exposure to a stimulus. It is called desensitization. The 
activation of second messenger-dependent protein kinases can modulate nAChR function 
through phosphorylation.16 The desensitization of nAChR has been observed by protein kinase A 
and protein kinase C through phosphorylation.15,17 Receptor desensitization has also been 
observed that the agonist itself results in an agonist-induced conformational change in the 
receptor after prolonged receptor exposure to the agonist.18 When an agonist is bound with a 
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positive allosteric modulator, desensitized receptors can be restored back to a prolonged open 
state.19 
 
1.9. Nicotinic acetylcholine receptor roles 
 
The subunits of the nicotinic receptors are the members of a multigene family (17 
members in human). The combinations of those subunits create a huge number of different 
receptor subtypes. These receptor subtypes have highly variable kinetic, electrophysiological and 
pharmacological properties and exhibit different responses to nicotine dependent on very 
different effective concentrations. This functional diversity divides them in two major types of 
neurotransmission. One is classical synaptic transmission (wiring transmission) that involves 
acting on immediately neighbouring receptors and the release of a neurotransmitter at high 
concentrations. Second is paracrine transmission (volume transmission). This involves the 
release of neurotransmitters by synaptic buttons. These synaptic buttons try to reach their 
receptors by diffusion through the extra-cellular medium and may be distant. The muscular 
nicotinic receptor generally functions post-synaptically. This is one of the examples in which the 
nicotinic receptors exist in different synaptic locations.20  
 
1.10. Nicotine 
 
Nicotine is one of the alkaloids that exist in the nightshade family of plants (Solanaceae). 
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Nicotine concentration is approximately 0.6-3.0% of the dry weight of tobacco.21,22 It is 
biosynthesized in the roots, but accumulated in the leaves. One of its functions is to serve as an 
antiherbivore chemical defense with particular specificity to insects. In the past nicotine has been 
widely used as an insecticide. Today certain nicotine analogs, such as imidacloprid (3) (Figure 
1.3) are still in use for such purpose. 
 
Figure 1.3. Structure of imidacloprid 
 
NCl
Imidacloprid 3
N N
N N O
O
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The name of nicotine came from the tobacco plant Nicotiana tabacum. In 1560, a French 
ambassador in Portugal named Jean Nicot de Villemain sent tobacco and seeds from Brazil to 
Paris and started their medicinal use. Then the plant was called Nicotiana tabacum after the 
name of Jean Nicot de Villemain. German chemists Posselt & Reimann first isolated nicotine 
from the tobacco plant in 1828, but it was not until 1843, that its chemical empirical formula was 
described by Melsens.23 The structure of nicotine was confirmed by Garry Pinner in 1893. The 
first synthesis of nicotine was done by A. Pictet and Crepieux in 1904. 
At low concentration (an average cigarette gives 1 mg of nicotine absorbed during 
smoking), nicotine plays a role as a stimulant in mammals. It is one of the main reasons that 
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tobacco smoking has the dependence-forming properties. American Heart Association says that: 
"Nicotine addiction has historically been one of the hardest addictions to break." The 
pharmacological and behavioral characteristics indicate that tobacco addiction is similar to 
addictions caused by other drugs such as heroin and cocaine.24 
 
1.11. Epibatidine 
 
Epibatidine (4) is an amphibian alkaloid that was first isolated from the skin of 
Epipedobates tricolor, a neotropical poisonous frog, found in the rainforest of Ecuador. The first 
isolation was done by John Daly at the National Institutes of Health. Later it was discovered that 
epibatidine was about 200 times more potent than morphine as an analgesic.25 Because of the 
scarcity of epibatidine from natural sources, a number of research groups have reported the 
syntheses of this unique alkaloid.26  
 
Figure 1.4. Structure of epibatidine and tebanicline 
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Studies with epibatidine have shown that the compound acts more like nicotine and 
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shows binding and activation of nicotinic acetylcholine receptors and has very little affinity at 
opioid receptors. Because of the toxicity of epibatidine, it is not an ideal candidate for clinical 
use. However the compound has provided new leads for the design of new analgesics.27 
Among all the epibatidine derivatives that have been tested, the most promising one 
reported up to date is ABT-594 [Tebanicline (5), Abbott Laboratories] (Figure 1.4). ABT-594 was 
found to be 50 times more potent than morphine and there was no paralysis or depression of 
muscle action indicated in animal tests. Phase II clinical trials have been completed in Europe. 
When humans with neuropathic pain were treated by ABT-594, clinical efficacy did show up as 
well as some unacceptable incidence of gastrointestinal side effects.28 As a result further 
development was halted. More research in this area is ongoing.29 
 
Figure 1.5. Superposition of nicotine and epibatidine25 [Nicotine (cyan) and epibatidine (red). 
Nitrogens are blue; chlorine is green.] 
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Nicotine and epibatidine have very similar structures. They both have a pyridine ring. 
They both have a basic nitrogen that contains ring system linked to the pyridine ring. In nicotine, 
there is one carbon between the nitrogen and pyridine ring, while the linkage in epibatidine is 
two carbons. The basic nitrogen is a part of a five-membered ring in both molecules. The five 
membered ring is a part of the azabicycloheptane structure in epibatidine. Dukat et al. have 
explored energy-minimized molecular models of these two compounds.30 The optimized 
structures of nicotine and epibatidine could be overlayed with similar position of the various 
structural features in space (Figure 1.5). This modeling experiment was the first to show in a 
three dimensional fashion that epibatidine and nicotine may interact with similar receptor 
features. 
 
1.12. Half maximal inhibitory concentration (IC50) 
 
The half maximal inhibitory concentration (IC50) is a measure to determine the 
effectiveness of a compound in performing biological or biochemical inhibitor function. This 
quantitative measure shows the concentration of a special drug or other compounds (inhibitors) 
that is required to inhibit an existing biological process (or parts of a process, for instance: an 
enzyme, cell, cell receptor microorganism) by half. This is called the half maximal (50%) 
inhibitory concentration (IC) of a substance (50% IC, or IC50). It is widely used to measure the 
potency of an agonist or antagonist drug in pharmacological research. The pIC50 is converted 
from IC50 by a log function of IC50. In the scale of pIC50, higher value shows exponentially 
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greater potency of a drug candidate. Referring to the FDA, IC50 demonstrates the concentration 
of a drug that is needed for 50% inhibition in vitro. While EC50 demonstrates the plasma 
concentration needed for gaining 50% of a maximum effect in vivo.  IC50 and EC50 are 
comparable for an agonist drug. 
Functional antagonist assays are used to determine the IC50 of a drug. A dose-response 
curve needs to be constructed. The effect of different concentrations of antagonist on reversing 
agonist activity is required for examination. These procedures determine the IC50 of a drug. The 
values of IC50 can be figured out for an existing antagonist by determining the concentration 
required to inhibit half of the maximum biological response of the agonist. 
The IC50 values are often dependent on the conditions when these measurements are 
taken. Normally, the higher IC50 value of inhibitor, the lower activity of an agonist will be. The 
increasing of enzyme concentration results the increasing of IC50 value. IC50 value may also be 
affected by other factors on the type of inhibition. For example, IC50 value for dependent 
enzymes doesn’t depend on the concentration of ATP. The potency of two antagonists can be 
compared by IC50 values. 
In the type of competition binding assay, a single concentration of radiolabelled ligand 
(normally an agonist) is employed in every assay tube. A low concentration below its Kd 
(dissociation constant) is used for the ligand. A range of concentrations of other competing 
non-radioactive compounds (normally antagonists) is presented. The scale of specific binding of 
the radiolabelled ligand is determined. The potency of these compounds that compete for the 
binding of the radiolabelled ligand can be measured. In order to compare in vitro potencies 
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among different ligands from different laboratories, the Ki value is often used. Derived by 
Cheng-Prusoff, the Ki value is not as dependent upon experimental conditions and allows direct 
comparison of data obtained from different laboratories. 
 
Ki = IC50/{[L]/Kd+1}                                              Equation 1 
 
As shown in Equation 1, the Ki value is determined from the IC50 value. [L] = the concentration 
of free radioligand used in the assay, and Kd = the dissociation constant of the radioligand for the 
receptor. 
 
IC50 value means the concentration of competing ligand which displaces 50% of the 
specific binding of the radiolabelled ligand in this case. IC50 value can not directly indicate the 
affinity, but the Cheng-Prusoff equation can relate IC50 and affinity at least for competitive 
agonists and antagonists.31  
 
1.13. Half maximal effective concentration (EC50) 
 
The half maximal effective concentration (EC50) is the concentration of a drug or 
antibody which generates a response halfway between the baseline and maximum value. It is 
widely used as a measure of drug potency as well as IC50. In a graded dose response curve, EC50 
means the concentration of a compound or a drug where 50% of its maximal effect is occurred. 
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While in a quantitative dose response curve, EC50 indicates the concentration of a compound or a 
drug where 50% of the population give a response. 
IC50 and EC50 are related but different. IC50 is routinely used for the summary measure of 
the dose-response curve for competition binding assays and functional antagonist assays. While 
EC50 is the widely used one for the summary measure of agonist/stimulator assays. The 
concentration normally follows a sigmoidal curve and a small change in concentration results in 
a rapid increase. Alternately, the IC50 value is the point at which the effectiveness slows with 
increasing concentration.  
 
1.14. Amphibian alkaloids 
 
Plants normally produce and store nitrogenous secondary metabolites that are called 
alkaloids. Beyond the plant kingdom, there are a diverse array of alkaloids that come from 
amphibian skins. Amphibian alkaloids are the lipophilic alkaloids that have been detected in 
amphibian skin. Normally these skin alkaloids are toxic and are obviously used in chemical 
defense against predators.32 The most recent review summarized about 24 classes of over 800 
amphibian alkaloids in 2005.33 As time goes on, more and more amphibian alkaloids will be 
detected and characterized. A lot of structures have been confirmed and established and there 
have been revisions of some previously proposed structures as spectroscopic techniques improve.  
In 1978 less than 100 amphibian alkaloids had been classified.34 More than 200 alkaloids 
were classified by 1987,35 and the number went up to 300 in 1993.36 A review in 1999 included 
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about 500 alkaloids.37 The classification was named after the nominal molecular weight and an 
identifying letter all in bold style. Many alkaloids were extracted from amphibian skin and 
characterized using gas chromatographic (GC) mass spectrometry and GC-Fourier-transform 
infrared (FTIR) spectral analyses.  
In general, evidence indicates amphibian alkaloids are sequestered from dietary sources. 
Except for the European fire salamander and the pseudophrynamines, amphibian alkaloids are 
not synthesized by the skin of amphibians themselves. Diet is the main source for amphibian to 
obtain and store these alkaloids. For example, ants, beetles, millipedes, and other small 
arthropods, even some unknown creatures are food chain for amphibians. Among the 800 
amphibian skin alkaloids, only a few have been discovered in arthropods.33 It is believed that 
beetles possess the batrachotoxins and coccinelline-like tricyclics; ants and mites possess the 
pumiliotoxins; ants also possess the decahydroquinolines, izidines, pyrrolidines, and piperidines; 
millipedes possess the spiropyrrolizidines. Histrionicotoxins, lehmizidines, and tricyclic 
gephyrotoxins are also very likely from ants. The source of epibatidine is unknown but generally 
believed not to be from a dietary source. 
All the skin alkaloids compose an extraordinary chemical ecology in amphibian skin. The 
alkaloids derived from dietary arthropods are the secretions for defensive purpose. Dendrobatid 
alkaloids were specially named after the family frogs of Dendrobatidae in which those alkaloids 
were found. The batrachotoxins, the histrionicotoxins, the decahydroquinolines, the 
gephyrotoxins, the cyclopentaquinolizidines, epibatidine, the pumiliotoxins and related 
congeners are all belong to the class dendrobatid alkaloids.32  
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These alkaloids have aroused tremendous academic and pharmaceutical interest due to 
their structural diversity and biological activity. However, the paucity of these alkaloids from 
natural resources have made total synthesis the only practical method to provide sufficient 
material for intensive structural and biological activity studies. An ongoing project in our 
laboratory has developed synthetic strategies for the construction of amphibian alkaloids that 
exhibit pharmacological activity mediated by nicotinic receptor ion channels.38,39 
 
1.15 Anabasine 
 
(S)-Anabasine (6), (S)-anatabine (7) and anabaseine (8) are all pyridine alkaloids (Figure 
1.6). These alkoloids can be found in cigarette tobacco and have a high potency at the nAChR.39 
(S)-Anabasine (6) was found in the plant of Tree Tobacco (Nicotiana glauca).  Nicotiana glauca 
and Nicotiana tabacum are close relatives of the tobacco plant. Its structure is similar to nicotine 
(1), and at one time it was widely used as an insecticide. There is a trace presence of anabasine in  
 
Figure 1.6. Structure of anabasine, anatabine and anabaseine 
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smoking tobacco, and a person’s exposure to tobacco smoke can be indicated by anabasine.41 
The affinity of anabasine (6) for mouse brain is 30-fold lower than nicotine. However the 
efficacy of anabasine reaches 40% that of nicotine. Anabasine is a nAChR agonist. The Ki value 
at the subunit of α4β2 is 210 nM. A depolarizing block of nerve transmission will be generated in 
high doses, and nicotine poisoning like symptoms will be exhibited. Accumulating doses could 
cause death because of asystole.42 It is believed that teratogenesis in swine comes from large 
amounts of ingested anabasine.43 Both enantiomers exhibit an intravenous LD50 value from 
11 mg/kg to 16 mg/kg in mice. 44 
(S)-Anatabine (7) was found in the plant of Nicotiana tabacum and exhibits 
approximately half the potency of anabasine. Anabaseine (8) is a paralytic toxin discovered in 
the marine worm Paranemertes peregina.40 It is a partial agonist at the α4β2 subtype nAChRs. 
The affinity of anabaseine is 20-fold weaker for the α4β2 subunit nAChRs and 10% efficacy of 
nicotine was observed. At the ganglionic α7 subtype receptor, high efficacy was observed as well 
as high selectivity for this particular receptor subtype.40 
 
1.16 Noranabasamine 
 
(S)-Noranabasamine (9) (Figure 1.7) was isolated from a Colombian poison-dart frog.45 
Because only trace amount of this alkaloid can be obtained from the nature, the biological 
activity of noranabasamine has not been investigated. The dietary sources for frogs to 
accumulate noranabasamine in their skin remains a mystery. Based on the structure shown in 
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Figure 1.7, noranabasamine is a demethylated form of another alkaloid anabasamine (10). 
 
Figure 1.7. Structure of noranabasamine and anabasamine 
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(S)-Anabasamine (10) was found in the poisonous semi-shrub Anabasis aphylla of  
Central Asia.46 Because of the scarcity of anabasamine from the nature, only limited biological 
studies have been conducted in the Soviet Union in 1980s.47 Recent studies showed that the 
catalytic acitivity of the enzyme acetylcholinesterase can be inhibited by anabasamine.48 
Anti-inflammatory activity similar to indomethain was observed when anabasamine was orally 
applied to rats.49 Similar inhibitory effects has been observed for the steroids such as 
hydrocortisone.50 This observed effect should be the outcome from the activation of the adrenal 
cortex-hypothalamus-pituitary system. The piperidine alkaloid maybe play a role in 
strengthening the adrenergic system when it decreases the ptosis induced by reserpine. Reserpine 
is a compound that can blocks the dopamine-norepinephrine transformation in mice.50 
Another interesting aspect for anabasamine biological activity is that when anabasamine 
was administered to rats, the activity of hepatic alcohol dehydrogenase was increased and 
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ethanol levels were decreased in the blood stream.51 In addition, the adrenal regulated production 
of tryptophan pyrrolase was stimulated in the liver of those rats that were administered 
anabasamine.52  
All the previous studies with (S)-noranabasamine (9) and (S)-anabasamine (10) mostly 
focused on the isolation and purification of this alkaloid from other related alkaloids found in 
amphibian skin and plants specimen. The low concentrations in plants and amphibians, the 
difficulty in isolation and the limited source in nature make these compounds attractive targets 
for synthesis. Future studies on these alkaloids and their analogues would be easier if there were 
more practical ways to make them available to scientists. 
 
1.17. Gephyrotoxin 
 
Gephyrotoxin was first isolated and characterized in 1977 from the skin of tropical frogs 
Dendrobates histrionicus.53 The absolute configuration was based on X-ray analysis of the 
hydrobromide salt of gephyrotoxin (11). However, questions remain about the absolute 
configuration of gephyrotoxin isolated from frog skin.36,37,54 Only two gephyrotoxins 287C and 
289B (Figure 1.8) were discovered in nature. Gephyrotoxins are only found in very rare 
dendrobatid frog species of the genus Dendrobates. They were shown as minor alkaloids along 
with 19-carbon histrionicotoxins as major alkaloids in extracts. Histrionicotoxins and 
gephyrotoxins are always isolated from the same source. It is believed that ants and other small 
arthropods are most likely the origin.32 Gephyrotoxin 287C (11) showed relatively low toxicity  
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Figure 1.8. Structure of gephyrotoxin 287C and 289B 
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when mice were treated with a minimal toxic dose much higher than 500 ug. Initial studies 
revealed this compound as muscarinic antagonist with low activity.55 Recent studies have 
indicated it as a nontoxic noncompetitive blocker of nicotinic recepters.37 Gephyrotoxin was also 
revealed to have an association with a more complex and interesting array of neurological 
activities.56 The low natural abundance and unusual chemical and biological activities make this 
compound a attractive target for synthesis. 
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CHAPTER 2 
 
 
Hydroxyarylketones via Ring-Opening Reactions of Lactones with 
Aryllithium Reagents 
 
2.1. Abstract 
 
The regioselective ring opening of lactones (δ-valerolactone and γ-butyrolactone) with 
aryllithium reagents is reported for the construction of a series of δ-hydroxyarylketones and 
γ-hydroxyarylketones. 
 
Scheme 2.1. Abstract scheme 
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2.2. Introduction 
 
δ-Hydroxyketones have been reported to be useful building blocks for the construction of 
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both natural and non-natural compounds.1,2 The synthesis of these versatile intermediates has 
been achieved via a variety of methods that include the photooxidation of aryldihydropyrans,3 
oxidation of β-hydroxy-sulfones,4 and nucleophilic ring opening of δ-valerolactone (1).1,2,5-7 Of 
these methods, the latter has been the most widely used, however, little attention has been given 
to organolithium nucleophiles.  
Previous work in our laboratories led to the development of a synthetic process for the 
construction δ-hydroxy-pyridinylketone derivatives via the addition of pryridinyl-lithium 
reagents with δ-valerolactone.5 The success of this reaction has prompted a broader study of the 
scope and limitations. Herein we report the reactivity of a series of aryllithium and 
heteroaryllithium reagents with δ-valerolactone and γ-butyrolactone for the preparation of 
δ-hydroxyarylketone and γ-hydroxyarylketone derivatives. 
 
2.3. Results and discussion 
 
As summarized Table 2.1, a series of δ-hydroxyketones 3 were readily prepared from the 
reaction of 1 with a variety of aryllithium and heteroaryllithium reagents (General Method A). 
The organolithium reagents were initially generated in situ by treatment of the corresponding 
bromide with either n-butyllithium or tert-butyllithium in Et2O at -78 °C. The lactone 1 was then 
added to the organolithium solution. The reaction was then quenched with brine to furnish the 
δ-hydroxyketones 3 in high yields (Table 2.1).  
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Table 2.1. Ring-opening of δ-valerolactone (1) 
 
entry compound ArBr (2) BuLi (1.2 equiv) 3 (%yield)a 
1 a 
Br
 
t-BuLi 79 
2 b 
Br
 
t-BuLi 87 
3 c 
Br
Cl  
t-BuLi 72 
4 d 
Br
H3CO  
t-BuLi 90 
5 e 
Br
O2N  
t-BuLi --b 
6 f 
Br
NC  
t-BuLi --b 
7 g 
N
Br
 
n-BuLi 81 
8 h 
N
Br
 
n-BuLi 63 
9 i 
N
Br
H3CO  
n-BuLi 98c,d 
10 j 
Br
S  
n-BuLi 79 
aGeneral Method A, isolated yields. bIntractable mixture. c1.33 equiv of 1. dSee reference 5. 
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The δ-hydroxyketones generally existed as a mixture of chain-ring tautomers (3:4, > 
90:10), with the equilibrium favoring the open-chain form 3 (Scheme 2.2).8 
 
Scheme 2.2. Ring-opening of δ-valerolactone (1) 
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It is noteworthy that the reaction conditions did not tolerate strong electron-withdrawing 
groups on the aryl bromide (Table 2.1, entry 5, NO2; entry 6, CN). Presumably the sensitivity of 
these groups to the strongly basic and nucleophilic organolithium reagents led to the formation of 
intractable mixtures. In addition, no diol products formed from the subsequent addition of the 
organolithium to the hydroxyketones were observed. These results suggest that under the low 
temperature conditions the lactone 1 was more reactive toward nucleophilic attack than the 
newly formed ketones 3. As such it is possible to obtain the δ-hydroxyarylketones in high yield 
by simple control of the reaction stoichiometry. 
The ring-opening reaction was also explored with γ-butyrolactone (5) (Table 2.2). Using 
the reaction conditions established for 1 (General Method A), the reactivity of 5 differed 
significantly from that of the homologous lactone 1.  In general, the major products from the 
reaction of 5 with the various aryllithium reagents were the 1,1-diaryl-1,4-butanediols 6,9 while 
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the corresponding γ-hydroxyketones 7 were the minor products (Scheme 2.3). 
 
Scheme 2.3. Ring-opening of γ-butyrolactone (5) 
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The formation of diols 6a-d,j resulted from a second addition of the organolithium 
reagent to the corresponding ketone that was formed initially. These results suggest that the 
γ-hydroxyketones 7a-d,j are more reactive toward nucleophilic addition than the lactone 5. It 
was interesting to discover that the pyridinyllithium reagents 2g, 2h and 2i did not readily 
undergo the secondary addition reaction. Only the corresponding γ-hydroxyketones 7 were 
obtained in good yield with only trace amounts (< 10%) of the diols 6 present. Presumably the 
pyridinyl moiety of the ketones 7g, 7h and 7i sufficiently deactivated the carbonyl toward the 
addition of a second equivalent the organolithium reagent. As a result the more reactive lactone 5 
is consumed prior to the competing second addition. Even employing an excess of the 
pyridyllithium reagents (2.0 equiv) did not lead to increased production of the corresponding 
diols 6 but did lead to slightly diminished yields. 
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Table 2.2. Ring-opening of γ-butyrolactone (5) 
 
entry compound ArBr (2) BuLi (1.2 equiv) 6/7a 6/7b 
1 a 
Br
 
t-BuLi 65/16 9/71 
2 b 
Br
 
t-BuLi 72/18 10/67 
3 c 
Br
Cl  
t-BuLi 68/13 11/63 
4 d 
Br
H3CO  
t-BuLi 77/15 14/68 
5 g 
N
Br
 
n-BuLi c--/70  
6 h 
N
Br
 
n-BuLi c--/66  
7 i 
N
Br
H3CO  
n-BuLi c--/89  
8 j 
Br
S  
n-BuLi 70/20 23/75 
aGeneral Method A, isolated yields. bGeneral Method B, isolated yields. cTrace amounts of 6 (< 
10%) observed by NMR. 
 
With these results in hand, it was envisaged that the order of addition of the lactone 5 
may effect the product 6/7 distribution. To this end, the order of addition was reversed by 
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addition of a pre-cooled (-78 °C) solution of the aryllithium reagent in Et2O to a solution of 5 in 
Et2O at -78 °C (General Procedure B). For the aryl bromides 2a-d,j that were tested, all gave 
improved yields of the γ-hydroxyarylketone 7 over the corresponding diols 6 (Table 2.2). The 
γ-hydroxyarylketones 7 existed nearly exclusively in the open-chain tautomer form. Only trace 
amounts of the ring tautomers could be observed by nmr for 7g and 7h. 
 
2.4. Conclusion 
 
In summary, a series of δ-hydroxyarylketones and γ-hydroxyarylketones were 
synthesized through our general method A /B using δ-valerolactone and γ-butyrolactone. These 
hydroxyarylketones can be used for the construction of both natural and non-natural compounds. 
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2.6. Experimental section 
 
General Method A. Under an atmosphere of nitrogen, to a stirred solution of aryl bromide 2 (5 
mmol, 1.0 equiv) in dry Et2O (80 mL) was added a solution of BuLi in hexanes (6 mmol, 1.2 
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equiv) drop-wise over 15 minutes at -78 °C. The solution was stirred for an additional 15 
minutes at -78 °C and then a solution of lactone (1 or 5) (5 mmol, 1.0 equiv) in Et2O (20 mL) 
was added drop-wise. The reaction was allowed to warm to room temperature and stirred for 2 
hours. Brine (75 mL) was added to quench the reaction and the organic layer was removed. The 
aqueous layer was extracted with EtOAc (2 × 50 mL) and CHCl3 (2 × 50 mL). All the combined 
organic portions were dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (SiO2, hexanes/EtOAc) to afford 
hydroxyarylketone 3 or 7. 
 
General Method B. Under an atmosphere of nitrogen, to a stirred solution of aryl bromide 2 (5 
mmol, 1.0 equiv) in dry Et2O (40 mL) was added a solution of BuLi in hexanes (6 mmol, 1.2 
equiv) drop-wise over 15 minutes at -78 °C. The solution was stirred for an additional 15 
minutes at -78 °C and then added vial cannula to a solution of lactone (5) (5 mmol, 1.0 equiv) in 
Et2O (40 mL) at -78 °C. The reaction was allowed to warm to room temperature and stirred for 2 
hours. Brine (75 mL) was added to quench the reaction and the organic layer was removed. The 
aqueous layer was extracted with EtOAc (2 × 50 mL) and CHCl3 (2 × 50 mL). All the combined 
organic portions were dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (SiO2, hexanes/EtOAc) to afford the 
γ-hydroxyarylketone 7. 
 
 35
OH
O
 
5-Hydroxy-1-phenylpentan-1-one (3a).2 Compound 3a was prepared by General Method A and 
obtained as a slight yellow oil (565 mg, 79% yield). 1H NMR (400 MHz, CDCl3) δ 1.61-1.68 (m, 
2H), 1.79-1.87 (m, 2H), 1.99 (s, 1H), 3.02 (t, J = 7.1, 2H), 3.66 (t, J = 6.3, 2H), 7.45 (t, J = 7.9, 
2H), 7.55 (t, J = 7.4, 1H), 7.95 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 20.4, 32.4, 38.3, 62.6, 
128.3, 128.8, 133.3, 137.1, 200.7. Anal. Calcd. for C11H14O2: C, 74.13; H, 7.92. Found: C, 73.63; 
H, 7.98. 
 
OH
O
 
5-Hydroxy-1-p-tolylpentan-1-one (3b).1c Compound 3b was prepared by General Method A 
and obtained as a white solid (837 mg, 87% yield), mp 36-38 °C. 1H NMR (400 MHz, CDCl3) δ 
1.56-1.75 (m, 3H), 1.84 (m, 2H), 2.38 (s, 3H), 3.00 (t, J = 7.1, 2H), 3.67 (dd, J = 11.6, 6, 2H), 
7.26 (d, J = 7.3, 2H), 7.87 (d, J = 8.2, 2H). 13C NMR (101 MHz, CDCl3) δ 20.5, 21.9, 32.5, 38.2, 
62.5, 128.4, 129.5, 134.6, 144.1, 200.5. Anal. Calcd. for C12H16O2: C, 74.97; H, 8.39. Found: C, 
74.75; H, 8.49. 
 
OH
O
Cl  
1-(4-Chlorophenyl)-5-hydroxypentan-1-one (3c). Compound 3c was prepared by General 
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Method A and obtained as a white solid (0.77 g, 72% yield), mp 59-61 °C. 1H NMR (400 MHz, 
CDCl3) δ 1.61-1.69 (m, 3H), 1.80-1.88 (m, 2H), 3.00 (t, J = 7.1, 2H), 3.68 (dd, J = 11.6, 5.8, 2H), 
7.43 (d, J = 8.4, 1H), 7.90 (d, J = 8.5, 1H). 13C NMR (101 MHz, CDCl3) δ 20.4, 32.4, 38.3, 62.6, 
129.1, 129.7, 135.4, 139.7, 199.3. Anal. Calcd. for C11H13ClO2: C, 62.12; H, 6.16. Found: C, 
62.17; H, 6.10. 
 
OH
O
H3CO  
5-Hydroxy-1-(4-methoxyphenyl)pentan-1-one (3d).3 Compound 3d was prepared by General 
Method A and obtained as a colorless oil (933 mg, 90% yield). 1H NMR (400 MHz, CDCl3) δ 
1.60-1.68 (m, 2H), 1.77-1.85 (m, 2H), 2.01 (s, 1H), 2.96 (t, J = 7.1, 2H), 3.65 (dd, J = 10.7, 5.9, 
2H), 3.85 (s, 3H), 6.89-6.93 (m, 2H), 7.91-7.95 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 20.6, 
32.5, 38.0, 55.7, 62.5, 113.9, 127.5, 130.5, 163.7, 199.3. Anal. Calcd. for C12H16O3: C, 69.21; H, 
7.74. Found: C, 69.63; H, 7.74. 
 
N
OH
O
 
5-Hydroxy-1-(pyridin-2-yl)pentan-1-one (3g).10 Compound 3g was prepared by General 
Method A and obtained as a yellow oil (730 mg, 81% yield). 1H NMR (400 MHz, CDCl3) δ 
1.63-1.71 (m, 2H), 1.77-1.87 (m, 2H), 1.92 (s, 1H), 3.25 (t, J = 7.3, 2H), 3.69 (t, J = 6.1, 2H), 
7.46 (ddd, J = 7.5, 4.8, 1.0, 1H), 7.83 (td, J = 7.7, 1.7, 1H), 8.03 (d, J = 7.9, 1H), 8.66 (d, J = 4.7, 
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1H). 13C NMR (75 MHz, CDCl3) δ 19.5, 20.3, 25.5, 32.4, 35.8, 37.4, 62.5, 62.6, 95.1, 120.2, 
122.1, 123.6, 127.3, 137.2, 137.6, 147.7, 149.1, 153.5, 161.1, 202.1. Anal. Calcd. for C10H13NO2: 
C, 67.02; H, 7.31; N, 7.82. Found: C, 66.96; H, 7.46; N, 7.73. 
 
N
OH
O
 
5-Hydroxy-1-(pyridin-3-yl)pentan-1-one (3h).1d Compound 3h was prepared by General 
Method A and obtained as a yellow oil (350 mg, 63% yield). 1H NMR (400 MHz, CDCl3) δ 
1.64-1.72 (m, 2H), 1.83-1.99 (m, 3H), 3.06 (t, J = 7.1, 2H), 3.70 (t, J = 6.1, 2H), 7.43 (dd, J = 8.0, 
4.8, 1H), 8.25 (m, 1H), 8.77 (dd, J = 4.8, 0.8, 1H), 9.17 (d, J = 2.1, 1H). 13C NMR (101 MHz, 
CDCl3) δ 20.3, 32.2, 38.7, 62.3, 124.0, 132.4, 135.8, 149.6, 153.4, 199.4. Anal. Calcd. for 
C10H13NO2: C, 67.02; H, 7.31; N, 7.82. Found: C, 65.74; H, 7.39; N, 7.67. 
 
N
OH
O
H3CO  
5-Hydroxy-1-(6-methoxypyridin-3-yl)-pentan-1-one (3i).5 Compound 3i was prepared by 
General Method A and obtained as a pale yellow solid (1.0 g, 98% yield), mp 42-44 °C. 1H NMR 
(400 MHz, CDCl3) δ 8.80 (d, J = 2.4 Hz, 1H), 8.14 (dd, J = 8.7, 2.4 Hz, 1H), 6.79 (d, J = 8.7 Hz 
1H), 4.01 (s, 3H), 3.68 (t, J = 6.3 Hz, 2H), 2.97 (t, J = 7.1 Hz, 2H), 1.92 (brs, 1H), 1.81-1.87 (m, 
2H), 1.64-1.70 (m, 2H). 13C NMR (100 MHz, CDCl3) δ, 198.3, 166.9, 149.2, 138.4, 126.8, 111.4, 
62.5, 54.3, 38.2, 32.4, 20.4. Anal. Calcd. for C11H15NO3: C, 63.14; H, 7.23; N, 6.69. Found: C, 
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62.97; H, 7.19; N, 6.64. 
 
OH
O
S  
5-Hydroxy-1-(thiophen-2-yl)pentan-1-one (3j). Compound 3j was prepared by General 
Method A and obtained as a yellow oil (726 mg, 79% yield). 1H NMR (400 MHz, CDCl3) δ 
1.62-1.71 (m, 3H), 1.82-1.90 (m, 2H), 2.97 (t, J = 7.2, 2H), 3.67 (dd, J = 10.4, 6, 2H), 7.13 (dd, J 
= 4.9, 3.8, 1H), 7.63 (dd, J = 4.9, 1.1, 1H), 7.73 (dd, J = 3.8, 1.1, 1H). 13C NMR (101 MHz, 
CDCl3) δ 20.9, 32.3, 39.1, 62.4, 128.4, 132.2, 133.9, 144.4, 193.8. Anal. Calcd. for C9H12O2S: C, 
58.67; H, 6.56. Found: C, 58.50; H, 6.70. 
 
OH
OH
 
1,1-Diphenylbutane-1,4-diol (6a).1a Compound 6a was prepared by General Method A and 
obtained as a white solid (393 mg, 65% yield), mp 104-106 °C. 1H NMR (400 MHz, CDCl3) δ 
1.54-1.61 (m, 2H), 1.94 (s, 1H), 2.41 (t, J = 7.2, 2H), 3.24 (s, 1H), 3.63 (t, J = 5.6, 2H), 7.18-7.23 
(m, 2H), 7.27-7.32 (m, 4H), 7.39-7.43 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 27.4, 39.2, 63.3, 
78.1, 126.3, 127.0, 128.4, 147.3. Anal. Calcd. for C16H18O2: C, 79.31; H, 7.49. Found: C, 79.06; 
H, 7.55. 
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1,1-Ditolylbutane-1,4-diol (6b). Compound 6b was prepared by General Method A and obtained 
as a white solid (486 mg, 72% yield), mp 106-108 °C. 1H NMR (400 MHz, CDCl3) δ 1.53-1.62 
(m, 2H), 1.83 (s, 1H), 2.31 (s, 6H), 2.38 (t, J = 7.2, 2H), 2.94 (s, 1H), 3.64 (s, 2H), 7.10 (d, J = 
8.0, 4H), 7.29 (d, J = 8.2, 4H). 13C NMR (75 MHz, CDCl3) δ 21.2, 27.5, 39.2, 63.4, 78.0, 126.2, 
129.1, 136.5, 144.5. Anal. Calcd. for C18H22O2: C, 79.96; H, 8.20. Found: C, 79.66; H, 8.19. 
 
OH
OH
Cl
Cl  
1,1-Di(4-chlorophenyl)butane-1,4-diol (6c).9b Compound 6c was prepared by General Method 
A and obtained as a white solid (529 mg, 68% yield), mp 125-127 °C. 1H NMR (400 MHz, 
CDCl3) δ 1.50-1.60 (m, 2H), 2.11 (s, 1H), 2.37 (t, J = 7.1, 2H), 3.64 (t, J = 5.6, 2H), 3.83 (s, 1H), 
7.24-7.28 (m, 4H), 7.30-7.34 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 27.0, 39.3, 63.2, 76.5, 127.7, 
128.6, 133.0, 145.6. Anal. Calcd. for C16H16Cl2O2: C, 61.75; H, 5.18. Found: C, 61.76; H, 5.36. 
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1,1-Di(4-methoxyphenyl)butane-1,4-diol (6d). Compound 6d was prepared by General Method 
A and obtained as a colorless oil (584 mg, 77% yield). 1H NMR (400 MHz, CDCl3) δ 1.54-1.61 
(m, 2H), 1.73 (s, 1H), 2.36 (t, J = 7.6, 2H), 2.83 (s, 1H), 3.66 (m, 2H), 3.78 (d, J = 6.0, 6H), 
6.80-6.85 (m, 4H), 7.29-7.33 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 27.5, 39.4, 55.5, 63.4, 100.2, 
113.6, 127.5 139.8, 158.5. Anal. Calcd. for C18H22O4: C, 71.50; H, 7.33. Found: C, 70.69; H, 
7.26. 
 
OH
OH
S
S
 
1,1-Di(thiophen-2-yl)butane-1,4-diol (6j). Compound 6j was prepared by General Method A 
and obtained as a white solid (445 mg, 70% yield, mp 94-96 °C. 1H NMR (400 MHz, CDCl3) δ 
1.67-1.74 (m, 2H), 1.92 (t, J = 4.9, 1H), 2.48 (t, J = 7.0, 2H), 3.70 (dd, J = 10.8, 5.7, 2H), 4.33 (s, 
1H), 6.93-6.97 (m, 4H), 7.22 (dd, J = 4.9, 1.4, 2H). 13C NMR (75 MHz, CDCl3) δ 27.5, 42.9, 
63.2, 76.1, 123.9, 124.8, 126.9, 152.4. Anal. Calcd. for C12H14O2S2: C, 56.66; H, 5.55. Found: C, 
56.91; H, 5.83. 
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4-Hydroxy-1-phenylbutan-1-one (7a).6 Compound 7a was prepared by General Method B and 
obtained as a colorless oil (582 mg, 71% yield). 1H NMR (400 MHz, CDCl3) δ 1.84 (t, J = 5.3, 
1H), 1.99-2.06 (m, 2H), 3.14 (t, J = 6.9, 2H), 3.75 (dd, J = 5.9, 11.3, 2H), 7.43-7.48 (m, 2H), 
7.54-7.59 (m, 1H), 7.96-7.99 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 27.1, 35.5, 62.6, 128.3, 
128.8, 133.4, 137.1, 200.8. Anal. Calcd. for C10H12O2: C, 73.15; H, 7.37. Found: C, 72.88; H, 
7.42. 
 
OH
O
 
4-Hydroxy-1-p-tolylbutan-1-one (7b).4b Compound 7b was prepared by General Method B and 
obtained as a white solid (593 mg, 67% yield), mp 42-44 °C. 1H NMR (400 MHz, CDCl3) δ 1.86 
(s, 1H), 1.98-2.05 (m, 2H), 2.41 (s, 3H), 3.11 (t, J = 6.9, 2H), 3.75 (s, 2H), 7.27 (d, J = 8.0, 2H), 
7.88 (d, J = 8.2, 2H). 13C NMR (75 MHz, CDCl3) δ 21.9, 27.2, 35.5, 62.6, 128.4, 129.5, 134.6, 
144.2, 200.4. Anal. Calcd. for C11H14O2: C, 74.13; H, 7.92. Found: C, 73.98; H, 7.98. 
 
OH
O
Cl  
1-(4-Chlorophenyl)-4-hydroxybutan-1-one (7c).11 Compound 7c was prepared by General 
Method B and obtained as a colorless oil (628 mg, 63% yield). 1H NMR (400 MHz, CDCl3) δ 
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1.77 (s, 1H), 1.96-2.04 (m, 2H), 3.10 (t, J = 6.9, 2H), 3.74 (t, J = 6.0, 2H), 7.44 (d, J = 8.5, 2H), 
7.92 (d, J = 8.5, 2H). 13C NMR (75 MHz, CDCl3) δ 27.0, 35.4, 62.4, 129.1, 129.7, 135.4, 139.8, 
199.5. Anal. Calcd. for C10H11ClO2: C, 60.46; H, 5.58. Found: C, 60.66; H, 5.81. 
 
OH
O
H3CO  
4-Hydroxy-1-(4-methoxyphenyl)butan-1-one (7d).12 Compound 7d was prepared by General 
Method B and obtained as a white solid (657 mg, 68% yield), mp 46-48 °C. 1H NMR (400 MHz, 
CDCl3) δ1.93 (t, J = 5.2, 1H), 1.97-2.04 (m, 2H), 3.08 (t, J = 6.9, 2H), 3.74 (q, J = 5.7, 2H), 3.87 
(s, 3H), 6.93 (d, J = 9.0, 2H), 7.96 (d, J = 9.0, 2H). 13C NMR (75 MHz, CDCl3) δ 27.3, 35.2, 
55.7, 62.6, 114.0, 127.5, 130.6, 163.7, 199.4. Anal. Calcd. for C11H14O3: C, 68.02; H, 7.27. 
Found: C, 67.97; H, 7.37. 
 
N
OH
O
 
4-Hydroxy-1-(pyridin-2-yl)butan-1-one (7g).7 Compound 7g was prepared by General Method 
A and obtained as a yellow oil (577 mg, 70% yield). 1H NMR (400 MHz, CDCl3) δ 1.98-2.05 (m, 
2H), 2.57 (t, J = 5.7, 1H), 3.31 (t, J = 7.0, 2H), 3.70 (q, J = 6.0, 2H), 7.48 (ddd, J = 7.6, 4.8, 1.2, 
1H), 7.84 (td, J = 7.7, 1.7, 1H), 8.03 (d, J = 7.9, 1H), 8.66 (d, J = 4.7, 1H). 13C NMR (101 MHz, 
CDCl3) δ 27.8, 34.5, 62.2, 122.1, 127.5, 137.3, 149.1, 153.6, 202.7. Anal. Calcd. for C9H11NO2: 
C, 65.44; H, 6.71; N, 8.48. Found: C, 64.76; H, 7.04; N, 8.29. 
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N
OH
O
 
4-Hydroxy-1-(pyridin-3-yl)butan-1-one (7h).1d Compound 7h was prepared by General 
Method A and obtained as a light yellow solid (545 mg, 66% yield), mp 36-38 °C. 1H NMR (400 
MHz, CDCl3) δ 1.98-2.05 (m, 2H), 2.40 (t, J = 5.1, 1H), 3.13 (t, J = 7.0, 2H), 3.74 (dd, J = 11.3, 
5.8, 2H), 7.40 (dd, J = 8.0, 4.8, 1H), 8.23 (dt, J = 8.0, 2.0, 1H), 8.74 (dd, J = 4.8, 1.7, 1H), 9.16 
(d, J = 2.2, 1H). 13C NMR (101 MHz, CDCl3) δ 26.8, 35.6, 61.7, 124.0, 132.4, 135.8, 149.6, 
153.4, 199.4. Anal. Calcd. for C9H11NO2: C, 65.44; H, 6.71; N, 8.48. Found: C, 65.85; H, 6.82; N, 
8.45. 
 
N
OH
O
H3CO  
4-Hydroxy-1-(6-methoxypyridin-3-yl)butan-1-one (7i). Compound 7i was prepared by 
General Method A and obtained as a pale yellow solid (0.87 g, 89% yield), mp 35-37 °C. 1H 
NMR (400 MHz, CDCl3) δ 8.82 (d, J = 2.4 Hz, 1H), 8.15 (dd, J = 8.7, 2.5 Hz, 1H) 6.79 (d, J = 
8.7 Hz, 1H), 4.01 (s, 3H), 3.75 (d, J = 4.4 Hz, 2H), 3.08 (t, J = 6.9 Hz, 2H), 2.14 (s, 1H), 
1.98-2.05 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 198.5, 167.0, 149.3, 138.4, 126.8, 111.4, 62.3, 
54.3, 35.3, 27.0. Anal. Calcd. for C10H13NO3: C, 61.53; H, 6.71; N, 7.18. Found: C, 61.70; H, 
6.82; N, 7.03. 
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4-Hydroxy-1-(thiophen-2-yl)butan-1-one (7j).13 Compound 7a was prepared by General 
Method B and obtained as a colorless oil (641 mg, 75% yield). 1H NMR (400 MHz, CDCl3) δ 
1.87 (t, J = 5.3, 1H), 1.99-2.06 (m, 2H), 3.08 (t, J = 7.0, 2H), 3.75 (q, J = 5.8, 2H), 7.12-7.15 (m, 
1H), 7.64 (dd, J = 4.9, 1.0, 1H), 7.75 (dd, J = 3.8, 1.0, 1H). 13C NMR (75 MHz, CDCl3) δ 27.4, 
36.2, 62.4, 128.4, 132.3, 133.9, 144.4, 193.7. Anal. Calcd. for C8H10O2S: C, 56.44; H, 5.92. 
Found: C, 56.05; H, 6.10. 
 
2.7. References 
 
1. (a) Descotes, G.; Soula, J.-C. Bull. Soc. Chim. Fr. 1964, 5, 2636-2639. (b) Crich, D.; Huang, 
X.; Newcomb, M. Org. Lett. 1999, 1, 225-227. (c) Bailey, W. F.; Khanolkar, A. D. 
Tetrahedron 1991, 47, 7727-7738. (d) Ohkawa, S.; Terao, S.; Terashita, Z.; Shibouta, Y.; 
Nishikawa, K. J. Med. Chem. 1991, 34, 267-276. 
 
2. Rosenblum, S. B.; Bihovsky, R. J. Am. Chem. Soc. 1990, 112, 2746-2748. 
 
3. (a) Atkinson, R. S. Chem. Commun. 1970, 177. (b) Atkinson, R. S. J. Chem. Soc. 1971, 
784-788. 
 
4. (a) Fuji, K.; Node, M.; Usami, Y.; Kiryu, Y. J. Chem. Soc. Chem Commun. 1987, 449-450. (b) 
Fuji, K.; Usami, Y.; Kiryu, Y.; Node, M. Synthesis 1992, 852-858. 
 
5. Miao, L.; DiMaggio, S. C.; Shu, H.; Trudell, M. L. Org. Lett. 2009, 11, 1579-1582. 
 
6. Yang, S.-B.; Gan, F.-F.; Chen, G.-J.; Xu, P.-F. Synlett 2008, 16, 2532-2534. 
 
7. Gómez, I.; Alonso, E.; Ramón, D. J.; Yus, M. Tetrahedron 2000, 56, 4043-4052. 
 
 45
8. Whiting, J. E.; Edward, J. T. Can. J. Chem. 1971, 49, 3799-3806. 
 
9. (a) Vozza, J. F. J. Org. Chem. 1959, 24, 720-722. (b) Umio, S.; Ueda, I.; Nojima, H. J. Med. 
Chem. 1972, 15, 855-856. 
 
10. Shimizu, J.; Tsurki, T.; Yamagishi, Y.; Inchino, T. Japanese Patent JP06157459; Chem. Abstr. 
1994, 121:179498. 
 
11. Huang, N.; Xu, L. Youji Huaxue 1989, 9, 436-437. Chem. Abstr. 1989, 113:5301. 
 
12. Ramadas, S. R.; Sukumaran, K. B. Ind. J. Chem. 1970, 8, 470-471. 
 
13. Acheson, R. M.; Cooper, M. W. J. Chem. Soc. Perkin 1, 1980, 1185-1193. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46
CHAPTER 3 
 
 
Enantioselective Syntheses of Both Enantiomers of Noranabasamine 
 
3.1. Abstract 
 
Both the R and S enantiomers of the amphibian alkaloid noranabasamine were prepared 
in > 30% overall yield with 80 %ee and 86 %ee, respectively. An enantioselective 
iridium-catalyzed N-heterocyclization reaction with either (R)- or (S)-1-phenylethylamine and 
1-(5-methoxypyridin-3-yl)-1,5-pentanediol was employed to generate the 
2-(pyridin-3-yl)-piperidine ring system in 69-72 % yield. 
 
Scheme 3.1. Noranabasamine synthesis 
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3.2. Introduction 
 
The pharmacology of amphibian alkaloids has generated significant interest in these 
molecules over the past decade. Many of these compounds have aided in the elucidation of 
biological mechanisms and the development of lead compounds for the treatment of a wide 
variety of pathologies mediated by nicotinic acetylcholine receptors (nAChRs) and 
corresponding ion channels.1 However, the paucity of useful quantities of isolated amphibian 
alkaloids has led to a flurry of synthetic activity to make these compounds available for 
biological study. While many of the amphibian alkaloids possess unique chemical structures,1 the 
similarity between noranabasamine (1) isolated from the columbian poison dart frog Phyllobates 
terribilis,2 and plant alkaloids isolated from the tobacco species Nicotian tabacum [e.g., nicotine 
(2), anabasine (3)],3 as well as the central asian shrub Anabasis aphylla [anabasamine (4)],4 is 
noteworthy. The plant-derived piperidine alkaloids 2 and 3 are widely known to elicit their 
pharmacological effects via nAChRs.5 Anabasamine (4) has been much less studied but has been 
reported to inhibit acetylcholine esterase and exhibit anti-inflammatory activity.6 
Our interests in the development of new pharmacotherapies for nAChR mediated 
disorders and disease states7 prompted an investigation into the synthesis of the enantiomers of 
noranabasamine (1). It was our aim to develop an efficient synthesis of 1, that would provide 
sufficient quantities for biological evaluation. In addition, it was envisaged that the preparation 
of both antipodes of 1 would aid in the confirmation of the absolute configuration of the natural 
product which has yet to be unequivocally established.4 Herein we describe the first 
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enantioselective syntheses of both enantiomeric forms of noranabasamine. 
 
Figure 3.1. Noranabasamine (1) and related plant alkaloids 
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3.3. Results and discussion 
 
Our retrosynthetic analysis illustrated in Scheme 3.2 focused on the disconnection of the 
terminal pyridyl group (ring C) to afford a 2-substituted piperidine fragment 5 as our initial 
target. There are a variety methods for the enantioselective construction of 2-substituted 
piperidines,8 but the iridiumcomplex-catalyzed N-heterocyclization of primary amines with diols 
recently reported by Yamaguchi and co-workers seemed to be exceptionally well suited for the 
construction of the AB-ring system of 5 and has not been explored for the preparation of natural 
products.9 A diastereoselective N-heterocyclization with the appropriate chiral primary amine 
was envisaged for introduction of the single stereogenic carbon atom of the noranabasamine 
skeleton. The approach not only was deemed straightforward but also offered the flexibility for 
the preparation of various derivatives and analogues if structure-activity studies were warranted 
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in the future. 
 
Scheme 3.2. Retrosynthetic analysis of noranabasamine (1) 
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As illustrated in Scheme 3.3, the ketone 8 was prepared from 
5-bromo-2-methoxypyridine (7). Treatment of 7 with n-butyllithium followed by addition of 
δ-valerolactone to the lithiated pyridine solution afforded the ketone 8 in 98% yield. The  
 
Scheme 3.3. Preparation of ketone 8 
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ring-opening reaction proceeded regioselectively to give 8 without further nucleophilic addition 
to the carbonyl. 
 
Scheme 3.4. Initial proposed N-heterocyclization 
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Our initial approach was to generate a secondary chiral alcohol at the ketone position of 
8.10 As shown in Scheme 3.4, ketone 8 was reduced to the corresponding diol 9 using 
(S)-(-)-α,α-diphenyl-2-pyrrolidinemethanol as a chiral catalyst. The diol 9 was converted to 
ditosylate 10.11,12 We envisaged that the ditosylate 10 would undergo the N-heterocyclization 
with the treatment benzylamine.12 However after several attempts, none of the desired product 11 
was obtained through this route. 
The carbonyl group of 8 was then reduced to the hydroxyl moiety with BH3·SMe2 to 
furnish the racemic diol 12 in 88% yield (Scheme 3.5). With the diol 12 in hands, our attention 
focused on the enantioselective construction of the piperidine ring using N-heterocyclization 
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Scheme 3.5. Preparation of racemic diol 12 
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Scheme 3.6. Diastereoselective N-Heterocyclization 
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chemistry (Scheme 3.6). The diol 12 was heated at 110 °C in toluene with 
(R)-1-phenylethylamine13 in the presence of a catalytic amount (1.5 mol%) of (Cp*IrCl2)2 
(Figure 3.2) in a sealed reaction tube. The N-heterocyclization then proceeded 
diastereoselectively to provide the 2-substituted piperidine 13ab in 72% yield (13a:13b, dr, 95:5). 
The diastereoisomers were easily separated by column chromatography. The 2-substituted 
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piperidine 14ab was prepared in similar fashion from diol 12 using (S)-1-phenylethylamine 
(Scheme 3.6). The piperidine 14ab was obtained in 69% yield with a diastereomeric ratio of 
14a:14b equal to 95:5. On the basis of the work of Yamaguchi and co-workers, we initially 
assigned the stereochemistry at C2 of 13a as possessing an S-configuration and 14a as having an 
R-configuration. 
 
Figure 3.2. Structure of (Cp*IrCl2)2, BNPPA and IPrPd(η3-allyl)Cl 
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Presumably N-heterocyclization proceeds through th e formation of various imine and 
enamine intermediates.9 To ensure ourselves that epimerization/racemization of the two 
stereogenic centers had not occurred during the ringenerating process, it would be necessary to 
establish the enantiomeric integrity of the piperidine ring. Crooks and co-workers recently 
reported a procedure for the determination of the enantiopurity of anabasine and related alkaloids 
using NMR spectroscopy and the chiral shift reagent 1,1′-binaphthyl-2,2′-diylphosphoric acid 
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(BNPPA) (Figure 3.2).14 With this technique in mind, it was envisaged that the issue of the 
enantiopurity of the piperidine ring system would be more easily resolved with 1, due to the 
similar secondary amine structure of noranabasamine to the anabasine. 
 
Scheme 3.7. Synthesis of tricyclic compound 16 
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With the piperidine ring system 13a in hand, our attention was directed toward 
completing the synthesis of noranabasamine (1). On the basis of the initial stereochemical 
assignment of 1,2 it was assumed that the N-heterocyclization product 13a possessed the correct 
stereochemistry at C2. However, the conversion of 13a into 1 would require the manipulation of 
the methoxy group into a more suitable moiety to facilitate an aryl cross-coupling reaction. To 
this end, treatment of 13a with POCl3 furnished the 5-chloropyridin- 3-yl derivative 15 in 92% 
yield (Scheme 3.7). The Suzuki-Miyaura coupling of 15 with 3-pyridineboronic acid could be 
achieved using several different types of palladium/ligand systems.15 Initially we employed the 
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catalytic system reported by Nolan and co-workers for the coupling sequence using 
allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium(II) chloride [IPrPd(η3-allyl)Cl] 
(Figure 3.2) as a catalyst.16 This furnished the tricyclic compound 16 in 65% isolated yield. 
 
Scheme 3.8. Attempt to deprotect the tricyclic compound 16 
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As shown in Scheme 3.8, various conditions were attempted to deprotect the the tricyclic 
compound 16. They were: I: 10% (or 20%) Pd/C [or Pd(OH)2/C], H2 (1 atm or 50 PSI), 6N HCl 
(0 equiv or 2.0 equiv), EtOH, RT or 65 oC, 24 hr or 48 hr.9,17 II: TMSCH2CH2OCOCl, THF; 
Bu4N+F-.18,19 III: 10% Pd/C, NH4+HCOO-, Et2O, RT.20 IV: Na/NH3.21 Unfortunately, despite 
numerous attempts to remove the N-phenylethyl auxiliary group, none were successful. The 
increased basicity of the molecule and the additional steric hindrance around the nitrogen atom 
completely shut down the hydrogenolysis of the N-1-phenylethyl group. High pressure, high 
temperature, and extended reaction times either resulted in recovery of unreacted starting 
material or decomposition and formation of intractable mixtures. 
To avoid the problematic hydrogenolysis of 16, an alternative sequence of reactions was 
devised to prepare 1 (Scheme 3.9). The methoxy derivative 13a was subjected to hydrogenolysis  
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Scheme 3.9. Revised procedure of hydrogenation 
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Figure 3.3. Structure of Pd catalysts and ligands 
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conditions to furnish 17 and concomitant treatment with POCl3 provided the chloro analogue 18 
in 56% yield over the two-step procedure. This sequence was also applied to 14a and furnished 
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the corresponding 20 in 61% yield. 
For the final step, several conditions were attempted to optimize the Suzuki-Miyaura 
coupling reactions. They were: I: IPrPd(η3-allyl)Cl (Figure 3.2), t-BuONa, dioxane (Used for the 
synthesis of 16).16 II: Pd(OAc)2, K2CO3, DMF/H2O.22 III: Pd2(dba)3 (Figure 3.3), 
1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride (Figure 3.3), Cs2CO3, dioxane.23 All the 
above conditions gave low yields and difficulties of chromatography separations. 
 
Scheme 3.10. Synthesis of noranabasamine 
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We utilized Fu and co-workers’ report using Pd2(dba)3 (Figure 3.3) as coupling catalyst 
and PCy3 (Figure 3.3) as ligand (Scheme 3.10).24 These conditions for the coupling of 
3-pyridineboronic acid with 18 were found to be superior to other methods because of the ease of 
the workup and purification steps. This afforded the (S)-noranabasamine (-)-1 in 84% yield, 
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[α]25D = -32.9 (c 0.33, CH3OH). The NMR data of (-)-1 was identical to the reported data of the 
isolated material, and the optical rotation was also levorotatory.25 The synthesis of the 
(R)-noranabasamine (+)-1 {[α]25D +34.6 (c 0.5, CH3OH) from 20 provided additional support of 
a 2S-configuration of the natural antipode of noranabasamine. 
At this point we sought to establish the enantiopurity of the piperidine ring systems. As 
expected use of the chiral shift reagent BNPPA (Figure 3.2) afforded baseline resolution of the 
proton signals for H2, H6, and H2’’ of both enantiomers of 1.26 From the NMR study it was 
quite clear that the enantiopurity of (-)-1 was greater than 86% ee, and that of (+)-1 was greater 
than 80% ee. From these results it can be inferred that the diastereoselective N-heterocyclization 
reactions that furnished 13a and 14a (Scheme 3.6) are highly enantioselective (>80% ee) and 
consistent with previous studies.9 
 
Scheme 3.11. Synthesis of anabasine 
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Altering the sequence of chlorination and hydrogenation on 13a afforded another natural 
product, (S)-anabasine (-)-3 (Scheme 3.11). This afforded the (S)-anabasine (-)-3 in 41% yield 
over two steps, [α]25D = -36.5 (c 0.5, CH3OH). The synthesis of the (R)-anabasine (+)-3 {[α]25D 
+36.7 (c 0.6, CH3OH) from 21 was performed as the manner. 
 
3.4. Conclusion 
 
In summary, we have shown that the iridium-catalyzed N-heterocyclization reaction is a 
facile method for the efficient and enantioselective construction of 2-(pyridin-3-yl)-piperidine 
alkaloids. This reaction was a key step in the first total synthesis of both enantiomers of the 
amphibian alkaloid noranabasamine (1) in greater than 30% overall yield and has allowed us to 
establish the absolute configuration of the natural product as levorotatory. Additional studies 
with regard to the scope and limitations of this reaction system are ongoing and will be reported 
in due course. The biological evaluation of both enantiomeric forms of noranabasamine is 
currently under investigation and will be reported elsewhere. 
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3.6. Experimental section 
 
General Experimental Methods 
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Anhydrous toluene was purchased from Mallinckrodt Baker, Inc. Proton and 
carbon NMR were recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer at 
ambient temperature in deuterated chloroform (CDCl3), or methanol (CD3OD) from Cambridge 
Isotope Laboratories, Inc. 1H NMR chemical shifts are reported as δ values (ppm) relative to 
tetramethylsilane. 13C NMR chemical shifts are reported as δ values (ppm) relative to 
chloroform-d (77.0 ppm). For chiral shift NMR, more accurate integration was obtained using 
MestReNova® software. Optical rotations were measured on Autopol III autopolarimeter at the 
sodium D line (2 mL sample cell). Melting points (mp) were measured with an Electrothermal R 
Mel-Temp apparatus and are uncorrected. 
 
N
O
H3CO
OH
 
4-Hydroxybutyl-6-methoxypyridin-3-yl ketone (8). Under an atmosphere of nitrogen, to a 
stirred solution of 5-bromo-2-methoxypyridine (7, 2.50 g, 1.72 mL, 13.3 mmol, 1.0 equiv) in dry 
Et2O (80 mL) was added a solution of n-BuLi in hexanes (1.6M, 9.14 mL, 14.6 mmol, 1.1 equiv) 
dropwise over 15 minutes at -78 °C. The solution was stirred for an additional 15 minutes at -78 
°C and then a solution of δ-valerolactone (1.77 g, 17.7 mmol, 1.3 equiv) in Et2O (20 mL) was 
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added dropwise. The reaction was stirred at room temperature for 2 hours. Brine (75 mL) was 
added to quench the reaction and the organic layer was removed. The aqueous layer was 
extracted with EtOAc (2 × 50 mL) and CHCl3 (2 × 50 mL). All the combined organic portions 
were dried over MgSO4, filtered and concentrated using a rotary evaporator under reduced 
pressure. The residue was purified by flash column chromatography (SiO2, 20:80 
hexanes/EtOAc) to afford 2.75 g (98% yield) of 8 as a pale yellow solid, mp 42-44 °C. 1H NMR 
(400 MHz, CDCl3) δ 1.64-1.70 (m, 2H), 1.81-1.87 (m, 2H), 1.92 (b, 1H), 2.97 (t, J = 7.1, 2H), 
3.68 (t, J = 6.3, 2H), 4.01 (s, 3H), 6.79 (d, J = 8.7, 1H), 8.14 (dd, J =8.7, 2.4, 1H), 8.80 (d, J = 
2.4, 1H). 13C NMR (CDCl3) δ 20.4, 32.4, 38.2, 54.3, 62.5, 111.4, 126.8, 138.4, 149.2 166.9, 
198.3. Anal. Calcd. for C11H15NO3: C, 63.14; H, 7.23; N, 6.69. Found: C, 62.97; H, 7.19; N, 
6.64. 
 
NH3CO
OHOH
 
1-(6-Methoxypyridin-3-yl)pentane-1,5-diol (12). Under an atmosphere of nitrogen, to a stirred 
solution of ketone 8 (1.0 g, 4.78 mmol, 1.0 equiv) in dry toluene (30 mL) was added borane 
dimethyl sulfide complex (10M, 0.956 mL, 9.56 mmol, 2.0 equiv) dropwise at 40 °C. The 
mixture was stirred at 40 °C for 2 hours, quenched with methanol (20 mL) in an ice bath and 
concentrated under reduced pressure to remove the solvent. The residue was dissolved in brine 
(25 mL) and extracted with EtOAc (2 × 25 mL) and CHCl3 (2 × 25 mL). All the organic portions 
were combined, dried over MgSO4, filtered and concentrated using a rotary evaporator under 
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reduced pressure. The residue was purified by flash column chromatography (SiO2, EtOAc) to 
afford 0.88 g (88% yield) of 12 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.21-1.87 (m, 
6H), 2.33 (b, 2H), 3.62 (t, J = 6.3, 2H), 3.92 (s, 3H), 4.65 (t, J = 6.6, 1H), 6.74 (d, J = 8.6, 1H), 
7.61 (dd, J = 8.6, 2.3, 1H), 8.07 (d, J = 2.1, 1H). 13C NMR (CDCl3) δ 22.1, 32.3, 38.5, 53.8, 62.4, 
71.6, 111.0, 133.4, 137.2, 144.5, 163.8. Anal. Calcd. for C11H17NO3: C, 62.54; H, 8.11; N, 6.63. 
Found: C, 61.56; H, 8.19; N, 6.52. 
 
N
N
H3CO Ph  
General Procedure A: N-Heterocyclization. 
(2S)-N-[(R)-1-Phenylethyl]-2-(5-methoxypyridin-3-yl)-piperidine (13a). The diol 12 (211 mg, 
1.0 mmol, 1.0 equiv.), [Cp*IrCl2]2 (3.0% Ir, 12 mg, 0.015 mmol, 0.015 equiv), KOAc (6.0%, 
5.88 mg, 0.06 mmol, 0.06 equiv), (R)-1-phenylethylamine (99% ee) (121 mg, 0.127 mL, 1.0 
mmol, 1.0 equiv) and toluene (1.0 mL) were placed under an atmosphere of argon in a 
high-pressure tube. The tube was sealed, and the mixture was stirred at the temperature of 110 °C 
for 17 hours. The resulting mixture was purified by preparative TLC (SiO2, 12:88 
hexanes/EtOAc) to afford 214 mg (72% yield) of 13a as slight yellow oil. [α]D25 +69.6 (c 1.15, 
CH3OH). 1H NMR (400 MHz, CDCl3) δ1.19 (d, J = 6.8, 3H), 1.26-1.80 (m, 6H), 2.22 (td, J = 
11.5, 2.4, 1H), 2.56 (d, J = 11.4, 1H), 3.49 (dd, J = 10.7, 2.8, 1H), 3.78 (q, J = 6.8, 1H), 3.92 (s, 
3H), 6.75 (d, J = 8.5, 1H), 7.17-7.42 (m, 5H), 7.77 (dd, J = 2.3, 8.5, 1H), 8.16 (d, J = 2.0, 1H). 
13C NMR (CDCl3) δ 8.4, 25.7, 26.4, 37.2, 45.3, 53.6, 55.2, 62.1, 111.5, 126.4, 127.7, 128.1, 
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133.4, 138.1, 144.6, 145.7, 163.8. Anal. Calcd. for C19H24N2O: C, 76.99; H, 8.16; N, 9.45. Found: 
C, 76.89; H, 8.09; N, 9.38. 
 
N
N
H3CO Ph  
(2R)-N-[(R)-1-Phenylethyl)]-2-(5-methoxypyridin-3-yl)-piperidine (13b). 1H NMR (400 MHz, 
CDCl3) δ 1.06-1.19 (m, 1H), 1.35 (d, J = 7.2, 3H), 1.39-1.72 (m, 5H), 1.78 (td, J = 11.7, 2, 1H), 
3.11 (m, 2H), 3.87 (q, J = 7.1, 1H), 3.97 (s, 3H), 6.79 (d, J = 8.5, 1H), 7.02 (d, J = 6.9, 2H), 
7.21-7.31 (m, 3H), 7.70 (dd, J = 8.5, 2.3, 1H), 8.12 (d, J = 2.2, 1H). 13C NMR (CDCl3) δ 18.9, 
25.2, 26.5, 38.3, 46.1, 53.6, 56.9, 62.5, 111.4, 127.0, 127.8, 129.0, 134.2, 138.2, 138.7, 146. 1, 
163.6. 
 
N
N
H3CO Ph  
(2R)-N-[(S)-1-Phenylethyl]-2-(5-methoxypyridin-3-yl)piperidine (14a). General procedure A 
was employed with 12 and (S)-1-phenylethylamine (99.5% ee) to afford 204 mg (69% yield) of 
14a as slight yellow oil. [α]D25 -62.8 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ1.19 (d, J = 
6.8, 3H), 1.30-1.80 (m, 6H), 2.22 (td, J = 11.6, 2.4, 1H), 2.56 (d, J = 11.4, 1H), 3.50 (dd, J = 10.8, 
2.4, 1H), 3.78 (q, J = 6.8, 1H), 3.92 (s, 3H), 6.74 (d, J = 8.5, 1H), 7.17-7.41 (m, 5H), 7.76 (dd, J 
= 8.5, 1.6, 1H), 8.16 (d, J = 2.2, 1H). 13C NMR (CDCl3) δ 8.4, 25.7, 26.4, 37.2, 45.3, 53.6, 55.2, 
62.2, 111.4, 126.4, 127.7, 128.1, 133.3, 138.1, 144.6, 145.7, 163.8. Anal. Calcd. for C19H24N2O: 
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C, 76.99; H, 8.16; N, 9.45. Found: C, 76.75; H, 8.04; N, 9.30. 
 
N
N
Cl Ph  
General Procedure B: Chlorination. 
(2S)-N-[(R)-1-Phenylethyl]-2-(5-chloropyridin-3-yl)piperidine (15). The piperidine 13a (0.40 
g, 1.4 mmol) was dissolved in POCl3 (3 mL) and sealed in a high-pressure reaction tube. The 
reaction was stirred at 120 °C for 17 hours. The cooled reaction mixture was slowly dripped into 
an ice-cold NaOH solution (2N, 75 mL) with continuous shaking to ensure each drop was well 
dissolved. The resulting mixture was extracted with EtOAc (2 × 50 mL) and CHCl3 (2 × 50 mL). 
All the organic portions were combined, dried over MgSO4, filtered and concentrated using a 
rotary evaporator under reduced pressure. The residue was purified by preparative TLC (SiO2, 
12:88 hexanes/EtOAc) to afford 373 mg (92% yield) of 15 as yellow solid, mp 66-69 °C. [α]D25 
+48.4 (c 0.5, CH3OH). 1H NMR (400 MHz, CDCl3) δ1.20 (d, J = 6.8, 3H), 1.28-1.81 (m, 6H), 
2.23 (td, J = 10.3, 2.4, 1H), 2.58 (d, J = 11.5, 1H), 3.56 (dd, J = 10.8, 2.4, 1H), 3.71 (q, J = 6.8, 
1H), 7.17-7.39 (m, 6H), 7.82 (dd, J = 8.2, 2.2, 1H), 8.43 (d, J = 1.6,1H). 13C NMR (CDCl3) δ 8.6, 
25.4, 26.1, 37.3, 45.1, 55.6, 62.1, 124.7, 126.6, 127.6, 128.2, 138.1, 139.8, 144.0, 149.2, 150.2. 
Anal. Calcd. for C18H21ClN2: C, 71.87; H, 7.04; N, 9.31. Found: C, 71.71; H, 6.97; N, 9.16. 
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N
N
Ph
N  
(2S)-N-(R)-1-Phenylethyl-noranabasamine (16). Under an atmosphere of argon, the piperidine 
15 (184 mg, 0.61 mmol, 1.0 equiv), pyridine-3-boronic acid (113 mg, 0.92 mmol, 1.5 equiv), 
allyl[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]palladium(II) chloride (35 mg, 0.0612 
mmol, 0.1 equiv), sodium tert-butoxide (118 mg, 1.2 mmol, 2.0 equiv ) were added to dry 
dioxane (10 mL). The reaction mixture was stirred vigorously at 90 °C for 8 hours. The cooled 
reaction mixture was filtered through celite 545 (2 g) and rinsed with EtOAc (5 mL) and CHCl3 
(5 mL). The filtrate was concentrated using a rotary evaporator under reduced pressure. The 
residue was purified by preparative TLC (SiO2, 30:70 hexanes /EtOAc) to afford 137 mg (65% 
yield) of 16 as light yellow oil. 1H NMR (CDCl3) δ 1.24 (d, J = 6.8, 3H), 1.92-1.33 (m, 6H), 2.27 
(td, 11.6, 2.8, 1H), 2.61 (d, J = 11.5, 1H), 3.64 (dd, J = 10.8, 2.4, 1H), 3.82 (q, J = 6.8, 1H), 7.20 
(t, J = 7.3, 1H), 7.30 (t, J = 7.6, 2H), 7.39 (dd, J = 4.8, 7.9, 1H), 7.44 (d, J = 7.5, 2H), 7.74 (d, J = 
8.1, 1H), 7.95 (dd, J = 8.0, 2.0, 1H), 8.31 (dt, J = 8.0, 1.6, 1H), 8.64 (d, J = 3.2, 1H), 8.78 (d, J = 
1.61H), 9.18 (s, 1H). 13C NMR (CDCl3) δ 8.6, 25.6, 26.3, 37.4, 45.2, 55.6, 62.7, 120.9, 123.8, 
126.6, 127.6, 128.2, 134.4, 135.0, 136.3, 140.1, 144.2, 148.4, 149.8, 150.0, 153.9. 
 
N
N
H
H3CO  
General Procedure C. Hydrogenolysis. 
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(S)-2-(5-Methoxypyridin-3-yl)-piperidine (17). The piperidine 13a (166 mg, 0.56 mmol), Pd 
on carbon (10%) (65 mg) and ethanol (20 mL) were stirred in a 100 mL round bottom flask 
under an atmosphere of hydrogen (1 atm) for 2 hours at 55 °C. The cooled reaction mixture was 
filtered through celite 545 (2 g) and rinsed with EtOAc (2 × 10 mL). The filtrate was 
concentrated using a rotary evaporator under reduced pressure to afford 17 as a light yellow oil 
that was carried on to next step without further purification. [α]D25 -22.9 (c 1.0, CH3OH). 1H 
NMR (400 MHz, CDCl3) δ 1.40-1.89 (m, 7H), 2.78 (td, J = 11.6, 2.4, 1H), 3.16 (d, J = 11.3, 1H), 
3.55 (dd, J = 10.4, 2.8, 1H), 3.91 (s, 3H), 6.70 (d, J = 8.5, 1H), 7.63 (dd, J = 8.5, 2.4, 1H), 8.09 
(d, J = 2.4, 1H). 13C NMR (CDCl3) δ 25.4, 25.9, 34.8, 47.9, 53.6, 59.4, 110.9, 133.7, 137.6, 
145.3, 163.8. 
 
N
N
H
Cl  
General Procedure D: Chlorination. 
(S)-2-(5-Chloropyridin-3-yl)piperidine (18). The unpurified piperidine 17 was dissolved in 
POCl3 (3 mL) and sealed in a high-pressure reaction tube. The reaction was stirred at 120 °C for 
1.5 hours. The cooled reaction mixture was slowly dropped into an ice-cold NaOH solution (2N, 
75 mL) with continuous shaking to ensure each drop was well dissolved. The resulting mixture 
was extracted with EtOAc (2 × 50 mL) and CHCl3 (2 × 50 mL). All the organic portions were 
combined, dried over MgSO4, filtered and concentrated using a rotary evaporator under reduced 
pressure. The residue was purified by preparative TLC (SiO2, 1:99 Et3N/EtOAc) to afforded 62 
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mg (56% yield, 2 steps) of 18 as a yellow solid, mp 53-57 °C. [α]D25 -27.8 (c 1.0, CH3OH). 1H 
NMR (400 MHz, CDCl3) δ 1.39-2.14 (m, 7H), 2.77 (td, J = 11.6, 2.8, 1H), 3.17 (d, J = 11.6, 1H), 
3.62 (dd, J = 10.5, 2.8, 1H), 7.24-7.27 (m, 1H), 7.69 (dd, J = 2.5, 8.2, 1H), 8.34 (d, J = 2.1, 1H). 
13C NMR (CDCl3) δ 25.3, 25.7, 35.1, 47.7, 59.2, 124.3, 137.5, 139.8, 148.6, 150.3. Anal. Calcd. 
For C10H13ClN2: C, 61.07; H, 6.66; N, 14.24. Found: C, 60.53; H, 6.62; N, 13.66. 
 
N
N
H
H3CO  
(R)-2-(5-Methoxypyridin-3-yl)-piperidine (19). General Procedure C using the piperidine 14a 
(158 mg, 0.53 mmol) afforded 19 as a light yellow oil that was carried on to next step without 
further purification. [α]D25 +24.2 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 1.41-1.97 (m, 
7H), 2.79 (td, J = 11.6, 2.8, 1H), 3.17 (d, J = 11.3, 1H), 3.56 (dd, J = 10.0, 2.4, 1H), 3.92 (s, 3H), 
6.70 (d, J = 8.5, 1H), 7.63 (dd, J = 2.4, 8.5, 1H), 8.09 (d, J = 2.4, 1H). 13C NMR (CDCl3) δ 25.5, 
25.9, 34.9, 48.0, 53.6, 59.5, 110.9, 133.9, 137.6, 145.2, 163.8. 
 
N
N
H
Cl  
(R)-2-(5-Chloropyridin-3-yl)-piperidine (20). General Procedure D using the unpurified 
piperidine 19 afforded 64 mg (61% yield, 2 steps) of 20 as yellow solid, mp 55-57 °C. [α]D25 
+28.4 (c 0.5, CH3OH). 1H NMR (CDCl3) δ 1.40-1.92 (m, 7H), 2.79 (td, J = 11.6, 2.8, 1H), 3.19 
(d, J = 11.6, 1H), 3.64 (dd, J = 10.8, 2.8, 1H), 7.28 (d, J = 8.1, 1H), 7.70 (dd, J = 8.2, 2.5, 1H), 
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8.36 (d, J = 2.4, 1H). 13C NMR (CDCl3) δ 25.3, 25.8, 35.2, 47.8, 59.3, 124.3, 137.5, 140.0, 148.6, 
150.2. Anal. Calcd. For C10H13ClN2: C, 61.07; H, 6.66; N, 14.24. Found: C, 61.27; H, 6.86; N, 
13.78. 
 
N
N
H
N  
General Procedure E: Suzuki-Miyaura Coupling Reaction. 
(S)-Noranabasamine [(-)-1]. The piperidine 18 (110 mg, 0.56 mmol, 1.0 equiv), 3-pyridine 
boronic acid (83 mg, 0.68 mmol, 1.2 equiv), [Pd2(dba)3] (5.2 mg, 0.0056 mmol, 0.01 equiv), 
PCy3 (3.8 mg, 0.014 mmol, 0.024 equiv), dioxane (1.5 mL) and aqueous K3PO4 (1.27M, 0.75 
mL, 0.95 mmol, 1.7 equiv) were placed under an atmosphere of argon in a high-pressure tube. 
The pressure tube was sealed and heated in an oil bath at 100 °C for 18 hours with vigorous 
stirring. The cooled mixture was diluted with EtOAc (10 mL) and CHCl3 (10 mL). The resulting 
mixture was dried over MgSO4, filtered through celite 545 (2 g) and rinsed with EtOAc (5 mL) 
and CHCl3 (5 mL). The filtrate was concentrated using a rotary evaporator under reduced 
pressure. The residue was purified by preparative TLC (SiO2, 2:98 Et3N/EtOAc) to afford 113 
mg (84% yield) of (-)-1 as a yellow solid, mp 81-83 °C. [α]D25 -32.9 (c 0.33, CH3OH). 1H NMR 
(CDCl3) δ 1.46-1.98 (m, 6H), 2.25 (bs, 1H), 2.83 (td, J = 11.6, 2.8, 1H), 3.23 (d, J = 11.4, 1H), 
3.71 (dd, J = 10.4, 2.4, 1H), 7.39 (dd, J = 8.0, 4.8, 1H), 7.72 (d, J = 8.1, 1H), 7.85 (dd, J = 8.2, 
2.2, 1H), 8.30 (dt, J = 8.1, 2.4, 1H), 8.64 (dd, J = 4.8, 1.6, 1H), 8.68 (d, J = 2.1, 1H), 9.18 (d, J = 
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2.4, 1H). 13C NMR (CDCl3) δ 25.4, 25.8, 35.0, 47.8, 59.7, 120.6, 123.8, 134.5, 135.0, 135.5, 
140.0, 148.4, 149.2, 150.0, 154.0. 
 
N
N
H
N  
(R)-Noranabasamine [(+)-1]. General Procedure E using 20 (94 mg, 0.48 mmol) afforded 69 
mg (76% yield, based upon recovered starting material) of (+)-1 as yellow solid, mp 78-80 °C. 
[α]D25 +34.6 (c 0.5, CH3OH). 1H NMR (CDCl3) δ 1.46-1.98 (m, 6H), 2.49 (bs, 1H), 2.83 (td, J = 
11.6, 2.4, 1H), 3.23 (d, J = 11.7, 1H), 3.72 (dd, J = 10.8, 2.4, 1H), 7.39 (dd, J = 8.0, 4.8, 1H), 
7.72 (d, J = 8.2, 1H), 7.87 (dd, J = 8.2, 2.2, 1H), 8.30 (dt, J = 8.0, 2.0, 1H), 8.64 (dd, J = 4.8, 1.6, 
1H), 8.69 (d, J = 2.0, 1H), 9.17 (d, J = 2.2, 1H). 13C NMR (CDCl3) δ 25.3, 25.7, 34.8, 47.8, 59.7, 
120.6, 123.8, 134.4, 135.0, 135.5, 139.8, 148.4, 149.2, 150.0, 154.0. 
 
N
N
Cl Ph  
(2R)-N-[(S)-1-Phenylethyl]-2-(5-chloropyridin-3-yl)piperidine (21). General Procedure B 
using the piperidine 14a (90 mg, 0.304 mmol) afforded 90 mg (90% yield) of 21 as yellow solid, 
mp 66-69 oC. [α]D25 -50.8 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ1.20 (d, J = 6.8, 3H), 
1.24-1.82 (m, 6H), 2.23 (td, J = 11.6, 2.6, 1H), 2.59 (d, J = 11.5, 1H), 3.57 (dd, J = 10.8, 2.7, 1H), 
3.71 (q, J = 6.8, 1H), 7.18-7.40 (m, 6H), 7.82 (dd, J = 8.2, 2.4, 1H), 8.43 (d, J = 2.3, 1H). 13C 
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NMR (CDCl3) δ 8.6, 25.4, 26.2, 37.4, 45.1, 55.6, 62.1, 124.7, 126.6, 127.5, 128.2, 138.1, 139.8, 
144.0, 149.1, 150.2. Anal. Calcd. for C18H21ClN2: C, 71.87; H, 7.04; N, 9.31. Found: C, 71.66; H, 
7.03; N, 9.19. 
 
N
N
H
 
General Procedure F. Hydrogenolysis. 
(S)-Anabasine [(-)-3]. The piperidine 15 (131 mg, 0.44 mmol), Pd on carbon (10%) (65 mg) and 
ethanol (20 mL) were stirred in a 100 mL round bottom flask under an atmosphere of hydrogen 
(1 atm) for 2 hours at 55 °C. The cooled reaction mixture was filtered through celite 545 (2 g) 
and rinsed with EtOAc (2 × 10 mL). The filtrate was concentrated using a rotary evaporator 
under reduced pressure. The residue was purified by preparative TLC plates (2:98 Et3N/EtOAc) 
to afford 32 mg (45% yield) of (-)-3 as sight yellow oil. [α]D25 -35.6 (c 0.5, CH3OH). 1H NMR 
(400 MHz, CDCl3) δ 1.44-1.99 (m, 7H), 2.81 (td, J = 11.6, 2.4, 1H), 3.21 (d, J = 11.4, 1H), 3.64 
(dd, J = 10.0, 2.4, 1H), 7.25 (dd, J = 8.2, 5.3, 1H), 7.73 (dt, J = 7.9, 1.6, 1H), 8.49 (dd, J = 4.8, 
1.2, 1H), 8.58 (d, J = 1.6, 1H). 13C NMR (CDCl3) δ 25.4, 25.8, 34.9, 47.8, 60.0, 123.7, 134.5, 
140.8, 148.8, 149.9. 
 
N
N
H
 
(R)-Anabasine [(+)-3]. General Procedure F using the piperidine 21 (141 mg, 0.48 mmol) 
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afforded 31 mg (40% yield) of (+)-3 as sight yellow oil. [α]D25 +36.7 (c 0.6, CH3OH). 1H NMR 
(400 MHz, CDCl3) δ 1.44-2.00 (m, 7H), 2.81 (td, J = 11.6, 2.8, 1H), 3.21 (d, J = 11.4, 1H), 3.64 
(dd, J = 10.2, 2.6, 1H), 7.25 (dd, J = 8.0, 4.8, 1H), 7.72 (dt, J = 8.0, 1.8, 1H), 8.49 (dd, J = 4.8, 
1.6, 1H), 8.59 (d, J = 4.8, 1.6, 1H). 13C NMR (CDCl3) δ 25.4, 25.9, 35.0, 47.9, 60.0, 123.7, 134.4, 
148.8, 148.9. 
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CHAPTER 4 
 
 
A Formal Synthesis of (+)-Gephyrotoxin-Kishi’s Intermediate 
 
4.1. Abstract 
 
A cis-2,5-disubstitued pyrrolidine building block derived from (-)-cocaine•HCl was 
prepared. We utilized this compound as a chiral building block for the formal synthesis of 
(+)-gephyrotoxin. Using this pyrrolidine building block, Kishi’s intermediate was obtained 
enantiospecifically in 15 steps and 9.4% overall yield. 
 
Scheme 4.1. General approach for the formal synthesis of Kishi’s intermediate 
 
(-)-Cocaine  HCl N
HO OMe
OCbz
N
HO
H
O
Kishi's intermediate  
 
4.2. Introduction 
 
Lipophilic alkaloids detected in amphibian skin have aroused tremendous academic and 
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pharmaceutical interest due to their structural diversity and biological activity. Over 800 
amphibian alkaloids comprising over 20 structural classes of alkaloids have been reviewed 
through 2005.1 However, the paucity of these alkaloids from natural resources have made total 
synthesis the only practical method to provide sufficient material for intensive structural and 
biological activity studies. An ongoing project in our laboratory has developed synthetic 
strategies for the construction of amphibian alkaloids that exhibit pharmacological activity 
mediated by nicotinic receptor ion channels.2,3 
 
Figure 4.1. Structure of amphibian alkaloids 
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At least four classes of these alkaloids are found to share the common structural feature 
of a cis-2,5-disubstitued pyrrolidine ring system. As shown in Figure 4.1, they are represented by 
the natural products: (+)-monomorine (1), cis-pyrrolidine 225H (2), lehmizidine 275A (3) and 
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(+)-gephyrotoxin (4). The structural similarity encouraged us to design a general and effective 
synthetic method that would allow enantioselective access to these compounds as well as their 
analogues. Our approach utilized the abundant natural product cocaine (5) as the starting material. 
Cocaine has four chiral centers, two of which can be directly introduced into the target molecules. 
We have previously completed and reported a synthesis of (-)-monomorine, the enantiomer of 
the natural product (+)-monomorine.4 
 
Figure 4.2. Structure of Kishi’s intermediate 
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Gephyrotoxin was first isolated and characterized in 1977 from the skin of tropical frogs 
Dendrobates histrionicus.5 Initial studies revealed this compound as muscarinic antagonist with 
low activity.6 Recent studies have indicated it as a nontoxic noncompetitive blocker of nicotinic 
recepters.7 Due to its interesting array of neurological activities and scarcity of this product in 
nature, several groups have conducted and reported the synthesis of gephyrotoxin in racemic or 
enantiopure forms.8-11 A few reported syntheses involved the common enantiopure tricyclic 
intermediate knowns as Kishi’s intermediate (6) (Figure 4.2). Compound 7 was synthesized both 
in Kishi and Lhomment’s work to get intermediate 6.10,12 We report herein an efficient formal 
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synthesis of (+)-gephyrotoxin (1) with a different approach to Kishi’s intermediate (6) other than 
the structure of 7. 
 
4.3. Results and discussion 
 
We have reported the synthesis of (-)-monomorine using Cbz-carbamate 9 derived for 
(-)-cocaine•HCl (5).4,13 The pyrrolidine building block 11 has been developed from 
Cbz-carbamate 8 through the intermediate methyl enol ether 10 (Scheme 4.2). While the 
instability of compound 9 encouraged us to revise the procedure of generating 
cis-2,5-disubstitued pyrrolidine building block. 
 
Scheme 4.2. Pyrrolidine building block in the synthesis of (-)-monomorine 
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Scheme 4.3. Revised procedure of pyrrolidine building block 
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As shown in Scheme 4.3, Cbz-carbamate 9 was readily available in our lab and was 
treated with NaH and TBDMSCl to furnish silyl enol ether 12 according to the procedure 
reported by Rassat and coworkers.14 Ether 12 was stable to chromatography for an excellent 
yield of 89%. The enol ether 12 was subjected to ozonolysis conditions the double bond was 
cleaved by ozone at -78 oC. The ozonide was reduced with NaBH4 in the subsequent step, then 
the reaction mixture was treated with CH2N2 to furnish our new pyrrolidine building block 13 
with 67% yield over three steps.4,14 It is noteworthy that the functional moiety at the C12 
position was introduced by the reduction with NaBH4 in the step after the ozonolysis. We still 
could use triphenylphosphine as we used before to keep the aldehyde moiety group ending with 
the same pyrrolidine building block 11.4 While in this case, NaBH4 was chosen as reduction 
reagent to generate alcohol moiety at C12 position. 
In order to install the C5 to our pyrrolidine building block 13, the alcohol function was 
converted to silyl ether 14 using TBDPS-Cl (Scheme 4.4).15 Then the protected building block 
14 was subjected to reduction using DIBAL-H to generate the corresponding aldehyde 15.4 
These two reactions went smoothly with a yield of 93% and 83% respectively. A Wittig 
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olefination reaction was employed to install the C5 unit using (Ph3PCH2OCH3)Cl and t-BuOK. 
The subsequent step was treated with PTSA·H2O and acetone ending with the desired aldehyde 
16 with 79% yield over two steps.4,14 The above reactions have been optimized and proved to be 
useful substrates for our pyrrolidine synthesis. 
 
Scheme 4.4. Installation C5 into pyrrolidine building block 
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With aldehyde 16 in hand, we could follow Kishi and Lhomment’s procedure for the 
construction of the tricyclic ring system (Scheme 4.5, Route A).8a,10,12 First, the aldehyde at the 
C5 position could be converted into the alcohol using NaBH4. Second, the Cbz protecting group 
would be removed by Pd/C under hydrogen atmosphere. Third, cyclohexane-1,3-dione could be 
coupled in the presence of  PTSA·H2O to form compound 17. Enolamine 17 is a similar 
structure compared to 7 which was generated through both Kishi and Lhomment’s routes, 
respectively. Using either Kishi or Lhommet’s route, there will be a two step reaction sequence 
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for converting compound 17 into the tricyclic compound 18 (the C12 silyl ether protected Kishi’s 
intermediate). The total synthesis requires five steps from 16 to 18 in Route A. 
 
Scheme 4.5. Proposed routes for cyclization 
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As shown in Scheme 4.5, Route B was our original proposed route for synthesizing the 
silyl ether protected Kishi’s intermediate (18). First, the aldehyde was treated by NaBH4 to 
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generate the corresponding alcohol at the C5 position. Second, the alcohol at C5 was converted 
to tosylate group by using TsCl. Third, cyclohexane-1,3-dione was attached using t-BuOK to get 
compound 19 which is our new approach to the Kishi’s intermediate (6). Structure 19 was 
different from compound 7 which was included in Kishi’s and Lhomment’s reports. Therefore, 3 
steps were employed already here. Compound 19 was subjected to cyclization under 1 
atmosphere of hydrogen to furnish the tricyclic compound 18 as the silyl ether protected Kishi’s 
intermediate. Route B was a 4 step procedure from 16 to 18. 
 
Scheme 4.6. Revised route for cyclization 
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In 2007, Kishor and Ramachary developed a methodology of coupling aldehydes with 
cyclohexane-1,3-dione with good yields based on different aldehyde substrates.16 Kishor and 
Ramachary’s methodology was employed in our pyrrolidine building block aldehyde 16 (Scheme 
4.6). Upon dissolving aldehyde 16 dissolved in dichloromethane, diethyl 
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2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate and cyclohexane-1,3-dione were added to 
the mixture in one portion.  Subsequently, L-proline was added as a catalyst in this reaction. 
The reaction was monitored by TLC and proceeded to completion within one hour. The reaction 
mixture was directly purified by chromatography to furnish compound 19 with an excellent yield 
of 93% without an aqueous workup. Then compound 19 was subjected to hydrogenation yielding 
the tricyclic compound 18 in 75%. The Cbz deprotection, cyclization and enolamine elimination 
occurred as one step. Our new synthetic route converted 16 to 18 in two steps with excellent 
yields compared to Routes A and B (Scheme 4.5). Structure 18 was confirmed by 13C NMR at 
positions C5a, C6 and C9a. Proton and carbon NMR indicated that the other diastereomer at the 
C3a position was present in 10%. The isomerization may have occurred during ozonolysis, 
DIBAL-H reduction or hydrogen cyclization. Our new route has less steps, is more efficient, and 
produces higher yields. In addition, our pyrrolidine building block is amenable to all of the above 
mentioned reactions with good yields. 
According to Gerasyuto and coworkers, the two diastereomers can be separated by 
chromatography after the deprotection of TBDPS group.11 Compound 18 was subjected to 
cleavage of TBDPS protection group at C12 position (Scheme 4.7).17 
Typical treatment with TBAF in THF resulted in Kishi’s intermediate (6) in 87% yield. 
NMR spectra and the melting point of 6 matched the literature data,10 and the absolute 
configuration of Kishi’s intermediate (6) has been confirmed by X-Ray crystallography (See 
appendix for details). 
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Scheme 4.7. Synthesis of (+)-gephyrotoxin (4)-Kishi’s intermediate (6) 
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4.4. Conclusion 
 
In summary, our pyrrolidine building block derived from (-)-cocaine•HCl (5) can be used 
for the synthesis of complex amphibian alkaloids. With this strategy, we have prepared Kishi’s 
intermediate (6) of (+)-gephyrotoxin (4) from (-)-cocaine•HCl (5) in 15 steps and 9.4% overall 
yield. Compared to previous syntheses of Kishi’s intermediate, our approach had less steps than 
Kishi’s route (18 steps) and a higher diastereoselective ratio than the route of Gerasyuto and 
coworkers. In addition, condensation reaction with cyclohexane-1,3-dione and subsequent 
intramolecular cyclization employed in Kishi’s route and Lhommet’s route were significantly 
improved by our new synthetic approach. 
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4.6. Experimental section 
 
General Experimental Methods 
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Anhydrous dichloromethane was purchased from Mallinckrodt Baker, Inc. 
Confiscated grade (-)-cocaine hydrochloride was provided by NIDA Drug Supply System, 
Research Technology Branch, National Institute on Drug Abuse. Proton and carbon NMR were 
recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer at ambient temperature 
in deuterated chloroform (CDCl3) from Cambridge Isotope Laboratories, Inc. 1H NMR chemical 
shifts are reported as δ values (ppm) relative to tetramethylsilane. 13C NMR chemical shifts are 
reported as δ values (ppm) relative to chloroform-d (77.0 ppm). Optical rotations were measured 
on Autopol III autopolarimeter at the sodium D line (2 mL sample cell). Melting points (mp) 
were measured with an Electrothermal R Mel-Temp apparatus and are uncorrected. 
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N
H3C
O
 
(1R,5S)-8-Methyl-8-azabicyclo[3.2.1]octan-2-one (8). A solution of (-)-cocaine hydrochloride 
(5) (34.0 g, 100 mmol) in concentrated hydrochloric acid (276 mL) was refluxed for 24 hours. 
After the mixture was cooled to room temperature, it was diluted with H2O (255 mL) and 
extracted with Et2O (2 × 255 mL) to remove benzoic acid. The aqueous phase was then 
evaporated under vacuum to dryness. The white solid was further dried under vacuum at 100 °C 
for 24 hours. This afforded crude white solid which without further purification was used in the 
next step. 
To finely powdered the previous step crude white solid (20.0 g, 98.2 mmol) in a 2 L round 
bottom flask were added Na2CO3 (25.4 g, 240 mmol) and 4-dimethylaminopyridine (DMAP) 
(305 mg, 2.50 mmol), and the vessel was sealed under an atmosphere of nitrogen. Dried CH2Cl2 
(366 mL) was added to the flask followed by addition of diphenylphosphorylazide (DPPA) (25.9 
mL, 0.12 mol). The reaction mixture was stirred vigorously for 48 hours. The solvent was 
removed under vacuum, and the resulting residue was then dissolved in H2O (106 mL) followed 
by the careful addition of 1N HCl (604 mL). The solution was then heated in a preheated oil bath 
(120 °C) for 35 minutes (until the carbon dioxide and nitrogen evolution ceased). The aqueous 
HCl was removed under vacuum, and the residue was made basic (pH 9.5-10.0) with a saturated 
solution of Na2CO3. The aqueous solution was extracted with CH2Cl2 (3 × 500 mL). The 
combined organic fractions were dried (Na2SO4) and the solvent was removed under vacuum. 
The resulting liquid was purified by vacuum bulb-to-bulb distillation (Kugelrohr). This afforded 
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8 (10.6 g, 76% yield, 3steps) as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ 1.67-1.78 (m, 
3H), 2.13-2.25 (m, 4H), 2.28-2.37 (m, 1H), 2.39 (s, 3H), 3.25-3.30 (m, 2H). 
 
N
O
Cbz
 
(1R,5S)-Benzyl 2-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (9). Benzyl chloroformate (18 
mL, 128 mmol) was added to a solution of 8 (3.6 g, 26 mmol) and potassium carbonate (180 mg, 
1.3 mmol) in toluene (80 mL). The solution was heated to reflux for 48 hours. The solvent was 
removed under reduced pressure, and the residue was dissolved in water (50 mL). The aqueous 
mixture was extracted with CH2Cl2 (3 × 50 mL), and the combined organic layers were dried 
over Na2SO4. The solvent was removed under reduced pressure, and the residue was purified by 
flash column chromatography (SiO2, 50:50 hexanes/EtOAc) to afford 9 (3.42 g, 56% yield) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.77-1.86 (m, 2H), 2.18-2.25 (m, 2H), 2.32-2.38 (m, 
2H), 2.42-2.48 (m, 2H), 4.45-4.51 (m, 2H), 5.11-5.17 (m, 2H), 7.27-7.36 (m, 5H). 13C NMR (75 
MHz, CDCl3) δ 27.8, 30.4, 32.4, 52.8, 64.1, 67.0, 127.8, 128.0 128.2, 128.4, 136.2, 153.8, 205.3. 
Anal. Calcd for C15H17NO3: C, 69.48; H, 6.61; N, 5.40. Found: C, 69.65; H, 6.74; N, 5.62. 
 
N
OTBS
Cbz
 
(1R,5S)-Benzyl 2-(tert-butyldimethylsilyloxy)-8-azabicyclo[3.2.1]oct-2-ene-8- 
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carboxylate (12). NaH (60 mg, 2.5 mmol, 5.0 equiv) was suspended in dry THF (4 mL) under 
nitrogen at 0 oC with ice bath. A solution of compound 9 (130 mg, 5 mmol, 1.0 equiv) in dry 
THF (2 mL) was added dropwise. The stirring was continued for 2 hours. Then TBDMSCl (1.0M 
in THF, 1 mL, 1 mmol, 2.0 equiv) was added dropwise at 0 oC. The stirring was continued 
overnight. At 0 oC, water (5 mL) was added slowly. The solution was extracted with Et2O (3 × 10 
mL). All combined organic portions were dried over MgSO4 and evaporated. The crude product 
was purified by flash column chromatography (SiO2, 95:5 hexanes/EtOAc) to afford 12 (166 mg, 
89% yield) as a colorless oil. [α]D25 -43.5 (c 1.2, CH3OH). 1H NMR (400 MHz, CDCl3) δ 0.14 
(m, 6H), 0.90 (s, 9H), 1.58-1.67 (m, 2H), 1.74 (dd, J = 16.4, 4.6, 1H), 1.94-2.18 (m, 3H), 
2.61-2.79 (m, 0.5H), 4.11-4.49 (m, 2.5H), 5.09-5.19 (m, 2H), 7.28-7.35 (m, 5H). 13C NMR (75 
MHz, CDCl3) δ -4.5, -4.1, 18.2, 25.8, 29.4, 30.2, 31.4, 32.4, 33.7, 34.4, 52.5, 57.7, 66.8, 97.3, 
128.0, 128.1, 128.6, 137.1, 154.4, 154.8. Anal. Calcd for C21H31NO3Si: C, 67.52; H, 8.36; N, 
3.79. Found: C, 67.73; H, 8.58; N, 3.79. 
 
N
HO OMe
OCbz  
(2R,5S)-1-Benzyl 2-methyl 5-(2-hydroxyethyl)pyrrolidine-1,2-dicarboxylate (13). Compound 
12 (781 mg, 2.1 mmol, 1.0 equiv) was dissolved in CH2Cl2 (50 mL) and CH3OH (5 mL). At -78 
oC, O3 was bubbled into the solution. Soon the solution showed a slight blue color. O3 was 
continued to bubble through the solution for 15 more minutes and then removed. N2 was bubbled 
through for 10 minutes. The solution was still kept at -78 oC. NaBH4 (250 mg) was added by one 
portion. After 30 minutes, another portion NaBH4 (300 mg) was added. The mixture was warmed 
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to room temperature. The solvent was removed under reduced pressure. The residue was 
triturated with 2N HCl (25 mL). The aqueous layer was extracted with CH2Cl2 (3 × 20 mL), and 
the combined organic layers were dried over MgSO4 and evaporated to afford an oil, which was 
used directly in the next step.  
To a stirred solution of the previous oil in Et2O (20 mL) at 0 oC, CH2N2 was bubbled through the 
solution until the yellow color shown up. Then the CH2N2 was stopped and N2 was bubbled 
through the solution for 30 minutes. The cold bath was removed and the resulting mixture was 
purified by flash column chromatography (SiO2, 40:60 hexanes/EtOAc) to afford 430 mg (67% 
yield, 3 steps) of 13 as a colorless oil. [α]D25 +52 (c 0.6, CH3OH). 1H NMR (400 MHz, CDCl3) δ 
1.61-1.82 (m, 3H), 1.95-2.11 (m, 2H), 2.30-2.37 (m, 1H), 3.60 (s, 3H), 3.64-3.82 (m, 3H), 3.93 
(dd, J = 9.8, 4.6, 1H), 4.37 (t, J = 8.3, 1H), 5.03-5.22 (m, 2H), 7.28-7.37 (m, 5H). 13C NMR (75 
MHz, CDCl3) δ 29.2, 30.9, 37.8, 52.4, 55.8, 59.1, 59.9, 67.8, 127.9, 128.3, 128.7, 136.4, 156.1, 
173.6. Anal. Calcd for C16H21NO5: C, 62.53; H, 6.89; N, 4.56. Found: C, 62.28; H, 7.00; N, 4.49. 
 
N
TBDPSO OMe
OCbz  
(2R,5S)-1-Benzyl 2-methyl 5-(2-(tert-butyldiphenylsilyloxy)ethyl)pyrrolidine-1,2- 
dicarboxylate (14). Compound 13 (374 mg, 1.22 mmol, 1.0 equiv) and imidazole (166 mg, 2.44 
mmol, 2.0 equiv) was dissolved in dry DMF (15 mL) under nitrogen at 0 oC. TBDPS-Cl (402 mg, 
0.374 mL, 1.46 mmol, 1.2 equiv) was added drop wise to the mixture. The mixture was allowed 
to warm to room temperature and stirred overnight. At 0 oC, H2O (15 mL) was added to the 
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mixture to quench the reaction. The mixture was extracted with Et2O (2 × 30 mL). The combined 
organic layers was dried over MgSO4 and evaporated under reduced pressure. The resulting 
mixture was purified by flash column chromatography (SiO2, 85:15 hexanes/EtOAc) to afford 
617 mg (93% yield) of 14 as a colorless oil. [α]D25 +22.1 (c 0.73, CH3OH). 1H NMR (400 MHz, 
CDCl3) δ 1.03 (d, J = 11.0, 9H), 1.61-2.02 (m, 4H), 2.15-2.40 (m, 2H), 3.58 (s, 1H), 3.65-3.79 
(m, 4H), 4.09-4.16 (m, 1H), 4.31-4.41 (m, 1H), 5.01-5.20 (m, 2H), 7.26-7.44 (m, 11H), 7.63 (t, J 
= 6.4, 4H). 13C NMR (101 MHz, CDCl3) δ 19.4, 27.0, 28.4, 29.4, 29.9, 30.2, 36.5, 37.2, 52.2, 
52.4, 56.5, 57.7, 59.9, 60.2, 61.7, 62.1, 67.0, 67.3, 127.9, 128.1, 128.6, 128.7, 129.8, 134.0, 135.8, 
136.9, 155.1, 173.6. Anal. Calcd for C32H39NO5Si: C, 70.43; H, 7.20; N, 2.57. Found: C, 70.64; 
H, 7.23; N, 2.56. 
 
N
TBDPSO H
OCbz  
(2S,5R)-Benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-formylpyrrolidine-1- 
carboxylate (15). Compound 14 (547 mg, 1 mmol, 1.0 equiv) was dissolved in toluene (6 mL) 
under nitrogen. At -78 oC, DIBAL-H (1.0M in toluene, 1.5 mL, 1.5 equiv) was added dropwise 
over a period of 45 minutes. The stirring at -78 oC was continued for additional 15 minutes and 
then the cold bath was removed. Et2O (10 mL), H2O (4 mL) and 15% NaOH (6 mL) were added 
one by one. After warmed to room temperature, the mixture was extracted with Et2O (2 × 20 mL). 
The combined organic layers was dried over MgSO4 and concentrated under vacuum. The 
resulting mixture was purified by flash column chromatography (SiO2, 80:20 hexanes/EtOAc) to 
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afford 431 mg (83% yield) of 15 as a colorless oil. [α]D25 +17.3 (c 0.95, CH3OH). 1H NMR (400 
MHz, CDCl3) δ 1.06 (d, J = 6.7, 9H), 1.43-2.45 (m, 6H), 3.59-3.80 (m, 2H), 4.13-4.27 (m, 2H), 
5.08-5.22 (m, 2H), 7.26-7.46 (m, 11H), 7.67 (s, 4H), 9.35 (s, 0.5H), 9.48 (s, 0.5H) 13C NMR (75 
MHz, CDCl3) δ 19.4, 24.9, 26.0, 27.1, 29.8, 30.1, 37.3, 37.8, 56.5, 57.7, 61.6, 61.8, 65.9, 66.3, 
67.4, 67.6, 127.9, 128.1, 128.3, 128.8, 129.9, 133.9, 135.8, 136.5, 154.7, 155.9, 200.5. Anal. 
Calcd for C31H37NO4Si: C, 72.20; H, 7.23; N, 2.72. Found: C, 71.88; H, 7.37; N, 2.61. 
 
N
TBDPSO
Cbz
H
O
 
(2S,5R)-Benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-(2-oxoethyl)pyrrolidine-1- 
carboxylate (16). (Ph3PCH2OCH3)Cl (1.25 g, 3.64 mmol, 1.33 equiv) was suspended in dry 
THF (50 mL) under nitrogen protection. t-BuOK (1.0M in THF, 3.42 mL, 3,42 mmol, 1.25 equiv) 
was added dropwise the solution. After 10 minutes, a solution of aldehyde 15 (1.412 g, 2.74 
mmol, 1.0 equiv) in dry THF (10 mL) was added dropwise. After the addition, the mixture was 
continued to stir for 2 hours. Then water (50 mL) was added to the mixture. The resulting 
solution was extracted with Et2O (2 × 50 mL). The combined organic layers was dried over 
MgSO4 and concentrated under vacuum to afford an oil, which was used directly in the next step. 
To a stirred solution of the previous oil in acetone (50 mL) at 0 oC, PTSA·H2O (260 mg, 1.37 
mmol, 0.5 equiv) was added as one portion. The cold bath was removed after the addition. The 
stirring was continued for additional 30 minutes. Most of the solvent was evaporated and water 
(50 mL) was added to the resulting mixture. The resulting solution was extracted with CH2Cl2 (2 
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× 50 mL). The combined organic layers was dried over MgSO4 and concentrated under vacuum. 
The crude product was purified by flash column chromatography (SiO2, 80:20 hexanes/EtOAc) 
to afford 1.145 g (79% yield, 2 steps) of 16 as a colorless oil. [α]D25 +2.44 (c 1.31, CH3OH). 1H 
NMR (400 MHz, CDCl3) δ 1.03 (s, 9H), 1.39-2.27 (m, 6H), 2.36-2.45 (m, 1H), 2.78-3.11 (m, 
1H), 3.69 (s, 2H), 4.04 (s, 1H), 4.22-4.36 (m, 1H), 5.10 (d, J = 6.2, 2H), 7.25-7.44 (m, 11H), 7.63 
(s, 4H), 9.71 (d, J = 52.8, 1H). 13C NMR (75 MHz, CDCl3) δ 19.4, 27.1, 27.7, 28.5, 29.7, 30.4, 
36.5, 38.4, 48.1, 50.3, 52.9, 54.2, 55.8, 56.4, 61.8, 67.0, 67.1, 127.2, 127.9, 128.1, 128.7, 129.9, 
133.9, 135.8, 136.8, 200.9 Anal. Calcd for C32H39NO4Si: C, 72.55; H, 7.42; N, 2.64. Found: C, 
72.55; H, 7.39; N, 2.57. 
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(2S,5S)-Benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-(2-(2,6-dioxocyclohexyl) 
ethyl)pyrrolidine-1-carboxylate (19). Aldehyde 16 (462 mg, 0.872 mmol, 1.0 equiv) was 
dissolved in CH2Cl2 (1.75 mL). Diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5- 
dicarboxylate (221 mg, 0.872 mmol, 1.0 equiv) and cyclohexane-1,3-dione (98 mg, 0.872 mmol, 
1.0 equiv) were added subsequently. Then L-proline (20 mg, 0.175 mmol, 0.2 equiv) was added 
to the mixture. The stirring was continued for 1 hour. The resulting mixture was directly 
subjected to purify by flash column chromatography (SiO2, 50:50 hexanes/EtOAc) to afford 509 
mg (93% yield) of 19 as a colorless oil. [α]D25 +42.1 (c 0.4, CH3OH). 1H NMR (400 MHz, 
CDCl3) δ0.98 (s, 9H), 1.35-1.97 (m, 11H), 2.15-2.54 (m, 6H), 3.60-3.81 (m, 3H), 4.00-4.09 (m, 
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1H), 5.15 (d, J = 2.0, 2H), 7.26-7.45 (m, 11H), 7.60-7.64 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 
14.4, 19.2, 19.4, 21.1, 27.0, 29.7, 30.0, 31.7, 37.0, 37.2, 39.2, 56.9, 58.7, 61.7, 67.8, 114.7, 127.9, 
128.2, 128.3, 128.7, 129.9, 133.8, 135.7, 199.4. Anal. Calcd for C38H47NO5Si·H2O: C, 70.88; H, 
7.67; N, 2.18. Found: C, 70.98; H, 7.46; N, 2.18. 
 
N
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H
O
 
(1S,3aS)-1-(2-(tert-Butyldiphenylsilyloxy)ethyl)-1,2,3,3a,4,5,8,9-octahydropyrrolo[1,2-a]qui
nolin-6(7H)-one (18). Compound 19 (473 mg, 0.756 mmol, 1.0 equiv) was dissolved in 
methanol (100 mL). 10% Pd/C (245 mg) was added to the solution. The mixture was subjected to 
hydrogenation with hydrogen balloon at room temperature for 24 hours. The resulting mixture 
was filtered through celite 545 (5 g) and rinsed with methanol (2 × 50 mL). All the combined 
filtrates were concentrated under vacuum. The residue was purified by preparative TLC (SiO2, 
95:5 EtOAc/CH3OH) to afford 270 mg (75% yield) of 18 as a yellow oil. [α]D25 +317 (c 0.31, 
CH3OH). 1H NMR (400 MHz, CDCl3) δ1.06 (d, J = 7.7, 9H), 1.13-1.28 (m, 1H), 1.38-2.20 (m, 
10H), 2.26-2.43 (m, 3H), 2.60-2.75 (m, 2H), 3.20-3.28 (m, 1H), 3.58-3.78 (m, 2H), 4.03 (t, J = 
8.6, 1H), 7.37-7.47 (m, 6H), 7.65 (dt, J = 8.0, 1.6, 4H). 13C NMR (75 MHz, CDCl3) δ 19.4, 20.3, 
21.6, 22.1, 27.1, 27.4, 27.6, 27.8, 28.6, 29.1, 29.8, 30.7, 36.3, 36.6, 38.5, 38.9, 55.7, 56.4, 57.3, 
59.4, 61.0, 61.4, 107.3, 128.0, 130.1, 133.6, 135.7, 135.8, 158.9, 193.9. Anal. Calcd for 
C30H39NO2Si·0.5H2O: C, 74.64; H, 8.35; N, 2.90. Found: C, 74.51; H, 8.28; N, 2.95. 
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(1S,3aS)-1-(2-Hydroxyethyl)-1,2,3,3a,4,5,8,9-octahydropyrrolo[1,2-a]quinolin-6(7H)-one (6). 
Compound 18 (174 mg, 0.367 mmol, 1.0 equiv) was dissolved in THF (5 mL). 
Tetrabutylammoniumfluoride (1.0M in THF, 0.55 mL, 0.55 mmol, 1.5 equiv) was added 
dropwise to the solution. The stirring was continued for 3 hours at room temperature. Then 
saturated Na2CO3 solution (0.5 mL) was added to the reaction mixture. After 10 minutes, Et2O 
(10 mL) was added to the mixture. The resulting mixture was dried over MgSO4 and filtered. The 
filtrate was concentrated under vacuum. The residue was purified by preparative TLC (SiO2, 
92:8 CH2Cl2/CH3OH) to afford 75 mg (87% yield) of 6 as a white solid, mp 178-180 oC 
(recrystallization from EtOAc/Cyclohexanes, 1:1) {lit.10: mp 176-179 oC}. [α]D25 +798 (c 0.29, 
EtOH) {lit.10: [α]D25 +538 (c 1.40, EtOH)}. 1H NMR (400 MHz, CDCl3) δ 1.18-1.29 (m, 1H), 
1.49-2.20 (m, 11H), 2.32 (t, J = 6.5, 2H), 2.40-2.48 (m, 1H), 2.61-2.68 (m, 2H), 3.23-3.31 (m, 
1H), 3.61-3.78 (m, 2H), 4.03 (t, J = 8.0, 1H). 13C NMR (75 MHz, CDCl3) δ 21.4, 21.9, 27.3, 
28.4, 29.0, 29.6, 36.3, 38.5, 55.6, 59.3, 60.0, 107.1, 158.9, 193.7. 
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CHAPTER 5 
 
 
First Multi-gram Preparation of SCP-123, 
A Novel Water Soluble Analgesic 
 
5.1. Abstract 
A large-scale process for the preparation of the analgesic compounds SCP-123 and its 
sodium salt, SCP-123ss•monohydrate has been developed. The process for the preparation of 
SCP-123 required three synthetic steps with no chromatography, while the process for the 
preparation of SCP-123ss required four synthetic steps and no chromatography. The overall 
yields for both SCP-123 and SCP-123ss were 47% and 46%, respectively, and both compounds 
were obtained in exceptionally high purity (>99%). 
 
Keywords: analgesic, acetaminophen, propacetamol, saccharin, hydrolysis, parenteral 
administration. 
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Figure 5.1. Structure of SCP-123 
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5.2. Introduction 
 
The analgesic acetaminophen (1) (Figure 5.2) is widely used for the acute and chronic 
control of pain.1 While the therapeutic window of 1 is quite broad, it does have some significant 
limitations. The low water solubility is problematic for some delivery applications, chronic use 
has significant hepatotoxicity, and acute use with alcohol can be lethal.2-4 A water-soluble 
analogue of 1 is the prodrug propacetamol hydrochloride (2).5,6 This form of acetaminophen is 
rapidly and completely hydrolyzed by plasma esterases to release 1.7 The pharmacological 
effects in clinical trials have shown that 2 possesses similar efficacy to 1, but due to its greater 
water-solubility can be parenterally administered and thus can be employed when oral 
administration is not possible.5,6 However, since 2 is a prodrug of 1, it still exhibits a similar 
pharmacological profile of side effects and toxicity. 
The recent discovery that the saccharin derivative of acetaminophen, SCP-1 (3) possesses 
analgesic properties of equal potency to acetaminophen with significantly diminished 
hepatotoxicity has prompted an extensive investigation into this class of compounds as a new 
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generation of analgesic drugs.8-12 The lead compound 3, was found to possess an analgesic and 
antipyretic profile similar to 1.10-12 However, recent studies with 3 have shown that it is 
extensively and rapidly hydrolyzed in vivo.10 The metabolite SCP-123 (4) and corresponding 
sodium salt SCP-123ss (5) are equipotent on a molar basis with 3 in analgesic models.13 
Presumably, the efficacy of 3 is derived from the hydrolysis products 4 and 5. Therefore, it was 
of interest to develop large-scale syntheses of 4 and 5 for further drug development studies.  
 
Figure 5.2. Structure of acetaminophen analogue 
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5.3. Results and discussion 
 
5.3.1. SCP-1 and analogues 
 
For the proposed initial studies, multigram quantities of 4 and 5 were required. Previous 
work with these compounds in our laboratories had revealed that the most efficient way to 
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prepare the gram quantities of these metabolites was via the hydrolysis of the saccharin ring of 
3.10 Therefore the design of a large-scale synthesis focused on the initial preparation of 3, 
followed by the subsequent hydrolysis to afford either 4 or 5. Two synthetic routes have been 
established for the preparation of gram quantities of 3.8-10 As illustrated in Scheme 5.1, the two 
routes primarily differ in the sequence in which the saccharin moiety is added to the acetyl unit. 
In Route A,9,10 the saccharin moiety is added in the last step to the 2-chloroacetamide 
intermediate 8 that has been previously generated from 4-aminophenol (6) and 2-chloroacetyl 
chloride (7). This yields 3 via a two-step process. Alternatively in Route B,8 the intermediate 
acetic acid intermediate 11 is formed initially from sodium saccharin (9) and bromoacetic acid 
(10). The intermediate 11 is then coupled to 4-aminophenol to furnish 3 also via a two-step 
process. 
Upon evaluation of both routes on a gram scale synthesis, Route A was deemed to be of 
greater merit due the low cost of the commercially available starting materials and the ease of 
purification of the intermediate 8 and SCP-1 (3). In Route A, the intermediate 8 precipitated 
cleanly from the reaction medium and could be obtained in a state of high purity (>95 %).  
Likewise in Route A, 3 could be obtained in greater that 95% purity by precipitation from the 
reaction media with ice water. Subsequently, a single recrystallization from ethanol/water 
routinely afforded 3 in pure form (>99%).  Alternatively, Route B seemed to be limited by the 
hygroscopic intermediate acid 11, which at times has been difficult to handle. In addition, the 
purification of 3 derived from Route B was found to require multiple recrystallizations to remove 
the impurity dicyclohexylurea, that is a by-product of the coupling reaction. 
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Scheme 5.1. Synthetic routes to SCP-1 (3) 
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Based upon our evaluation, Route A was scaled 15-fold and run on a mole scale based 
upon 4-aminophenol (6). The 2-chloroacetyl chloride (7) was added at a controlled rate to a 
suspension of 6 in a buffered solution of acetic acid [HOAc: NaOAc (sat.) (1:1, v:v)] such that 
the reaction temperature did not exceed 5 °C. Mechanical stirring was required to maintain 
adequate mixing throughout the reaction process. As the addition of the acid chloride progressed, 
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the suspension dissipated and the reaction mixture became clear. However, prior to the end of the 
addition of 7, precipitation of the intermediate 2-chloroacetamide 8 was observed. From this 
point on, mechanical stirring was essential to obtain consistent and high yields. The 
2-chloroacetamide intermediate 8 was obtained in 70% yield and no further purification was 
required for advancement to the next step. Preparation of 3 was routinely performed on a mole 
scale. The 2-chloroacetamide 8 and saccharin sodium salt (9) were heated to reflux in DMF with 
a catalytic amount of NaI (0.40 mol %). The saccharin derivative was then easily obtained by 
precipitation in ice water. A single recrystallization from ethanol/water furnished 3 in 72% yield.  
As illustrated in Scheme 5.2, the hydrolysis of 3 was readily achieved with NaOH 
solution followed by concomitant treatment with 2N hydrochloric acid.10,14  This afforded the 
corresponding acid 4 (SCP-123) in 93% yield.  
 
Scheme 5.2. Synthesis of SCP-123 (4) and SCP-123ss (5) 
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The hydrolysis reaction was not as easily scaled-up as the previous steps. This step in the 
sequence was routinely performed on a 50-gram scale. This limitation was due primarily to the 
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sensitivity of the hydrolysis step to the concentration of the saccharin derivative 3 in the basic 
solution. If the reaction mixture was not sufficiently dilute the formation of a side-product 12, 
that resulted from oxidative phenolic coupling, was obtained.15,16   
 
Figure 5.3. Structure of side-product 12 
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This impurity 12 was present in varying amounts, ranging from 10-25%, depending upon 
the concentration of the reaction mixture relative to 3. The coupling product 12 was difficult to 
detect by NMR and could only be identified and separated from the product 4 by HPLC.  An 
optimized concentration of 3 in 0.5N NaOH was determined to be 0.25 M. At this concentration, 
the hydrolysis of 3 proceeded cleanly and the oxidative-coupling product 12 was not observed. 
These conditions were preferred to using tedious degassing procedures and performing the 
reaction under anaerobic conditions. Due to the large reaction volumes at this concentration we 
were limited by our equipment and thus typically performed the hydrolysis on a 50-gram scale. 
The resultant hydrolysis product could be manipulated easily by precipitation with acid to give 4 
in > 99% purity. Despite the smaller scale of the hydrolysis reaction, this step was typically 
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executed in multiple simultaneous batches that could be combined to rapidly generate 
sub-kilogram quantities of 4. However, we have no evidence to suggest that this reaction is 
limited to this scale and could not be performed on a larger scale if needed. 
The preparation of the sodium salt 5 was achieved by titration of the acid 4 with one 
equivalent of sodium hydroxide (Scheme 5.2). The advantage of this procedure over the direct 
conversion of 3 into 5 was that the direct method gave an unquantifiable mixture of mono- and 
di-sodium salts due to the acidic phenol moiety. Alternatively, the titration of 4 with one 
equivalent of NaOH afforded the sodium carboxylate 5, which could be precipitated cleanly out 
solution as the mono-sodium salt. Filtration and vacuum drying gave 5 as the monohydrate 
(5•H2O) in quantitative yield and exceptionally high purity (>99%) as determined by HPLC and 
combustion analysis. The monohydrate 5•H2O, albeit somewhat hygroscopic, was stable to 
extensive drying and gave consistent combustion analysis when stored in dry environment. 
 
5.3.2. Synthesis of radiolabelled SCP-123 {[14C]-SCP-123} 
 
Because the price for radioactive 4-aminophenol (15) is so expensive, Route A (Scheme 
5.1) is not suitable for the synthesis of [14C]-SCP-1. On the other hand, Route B (Scheme 5.1) 
employed the N,N’-dicyclohexylcarbodiimdide (DCC) as a coupling reagent which generated a 
complicated work-up procedure and ended with a lower yield.8,17 Our new synthesis route started 
with commercial available saccharin (13). As shown in Scheme 5.3, we need to generate the 
intermediate 2-saccharin acetyl chloride using thionyl chloride. More dry the materials, the better 
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the yield of the reactions. In order to obtain anhydrous saccharin sodium salt (9) without any 
hydrate, saccharin (13) was treated with NaOH in reflux EtOH to afford saccharin sodium salt (9) 
precipitating out the solution at room temperature.1 Saccharin sodium salt (9) was coupled with 
2-chloroacetic acid (14) with catalytic amount of NaI in reflux DMF to form 2-saccharin acetic 
acid (11) in 86% yield.  
 
Scheme 5.3. Synthesis of [14C]-SCP-1 
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Compound 11 was treated with thionyl chloride under reflux for 2 hours to afford the 
intermediate 2-saccharin acetyl chloride which was used in the next step without further 
purification. The intermediate was dissolved in dry THF and dropwised to a precooled buffer 
solution of saturated NaOAc, HOAc and 4-amino-[14C(U)]phenol (1 mCi) at -10 oC over a 
period of 15 minutes. The amidation reaction went to complete with in 30 minutes to furnish 
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[14C]-SCP-1 (16) in 69% overall yield. Higher yield come from the slow addition of the acid 
chloride solution and 1.35 equivalents of the acid 11 relative to the 4-aminophenol. The reaction 
mixture was directly poured into ice water to form white precipitate which was filtered and dried 
under vacuum to afford NMR pure (> 95%) product. The whole procedure required no 
chromatography or recrystallizations. 
The synthesis of the metabolite [14C]-SCP-123 (17) was achieved by treatment of 
[14C]-SCP-1 (16) with 0.5N NaOH aqueous solution (Scheme 5.4). The hydrolysis reaction went 
to complete within 1 hour ending the ring open product [14C]-SCP-123 (17) in 80% yield. NMR 
pure (> 95%) product was obtained by adding 2N HCl to the reaction mixture followed by 
general work-up and recrystallization. 
 
Scheme 5.4. Synthesis of [14C]-SCP-123 
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5.3.3. Propacetamol hydrochloride 
 
In addition to the SCP compounds, propacetamol hydrochloride was synthesized to be 
used as standard in the biological evaluations (Scheme 5.5).18,19 Acetaminophen (1) was treated 
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with chloroacetyl chloride (7) in THF in the presence of pyridine to furnish p-acetamidophenyl 
chloroacetate (18) with 80% yield. 
 
Scheme 5.5. Synthesis of propacetamol hydrochloride 
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Compound 18 was coupled to diethylamine in the solvent of Et3N to form an intermediate 
p-acetamidophenyl diethylamino acetate. When HCl gas was bubbled through the solution of the 
intermediate in dry acetone, white crystals precipitated out the solution to afford propacetamol 
hydrochloride (2) with 41% yield. 
 
5.4. Conclusion 
 
In conclusion, we have developed a large-scale process for the preparation of 4 (SCP-123) 
and its sodium salt, 5•H2O (SCP-123ss•H2O). The overall yields for both 4 and 5•H2O were 
47% and 46% respectively. The process for the preparation of 4 required three synthetic steps 
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with no chromatography, while the process for the preparation of 5•H2O required four synthetic 
steps and no chromatography. In both processes, the desired compounds 4 and 5•H2O were 
isolated in high purity (> 99%) as determined by HPLC and combustion analysis. 
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5.6. Experimental section 
 
General Methods. All chemicals were purchased from Aldrich Chemical Company and used as 
received unless otherwise noted. All reactions were performed in glass reactors. Proton and 
carbon NMR were recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer at 
ambient temperature in deuterated dimethylsulfoxide (DMSO-d6) from Cambridge Isotope 
Laboratories, Inc.  1H NMR and 13C NMR chemical shifts are reported as δ values (ppm) 
relative to tetramethylsilane. Melting points (mp) were measured with an Electrothermal ® 
Mel-Temp apparatus and are uncorrected. HPLC was used to monitor the purity of all 
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intermediates using standard HPLC equipment with PDA detection and data system. Separations 
were performed with a Waters Nova-Pak C18 (3.9 × 150 mm) steel analytical column. The 
mobile phases for isocratic and gradient separations were prepared using 0.01% TFA in water 
and 0.01% TFA in CH3CN.  All the compounds were monitored against the reference materials 
including the starting materials. Combustion analysis (C, H, N) was performed by Atlantic 
Microlabs Inc., Norcross, GA. 
 
N
H
O
Cl OH
 
N-(4-Hydroxyphenyl)-2-chloroacetamide (8). The 4-aminophenol (6, 150 g, 1.37 mol,) was 
added to a saturated solution of sodium acetate (500 mL) in a three-neck 2 L-round-bottom flask 
fitted with a thermometer, addition funnel and mechanical stirrer. Acetic acid (500 mL) was 
added to the mixture and the suspension was cooled in an ice bath. The 2-chloroacetyl chloride 
(7, 155 g, 109 mL, 1.37 mol) was added portion wise to the suspension such that the reaction 
temperature did not exceed 5 °C. As the addition of 7 progressed the suspension dissipated and 
the mixture clarified. Prior to completion of the addition of 7, a white precipitate began to form. 
Upon completion of the addition, the heterogenous the mixture was stirred at room temperature 
for 2 hours. The white precipitate was filtered, washed with distilled water solution (2 × 100 mL) 
and dried under vacuum to afford 177 g of 8 as a white solid (70% yield), mp 142-144 °C. 1H 
NMR (400 MHz, DMSO) δ 4.17 (s, 2H), 6.70 (d, J = 8.8, 2H), 7.35 (d, J = 8.8, 2H), 9.26 (s, 1H), 
10.02 (s, 1H). 13C NMR (DMSO) δ 44.2, 115.9, 121.9, 130.7, 154.5, 164.6. Anal. Calcd. for 
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C8H8ClNO2: C, 51.77; H, 4.34; N, 7.55. Found: C, 51.87; H, 4.31; N, 7.49. 
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SCP-1 (3). The 2-chloroacetamide (8, 326 g, 1.75 mol) and saccharin sodium salt hydrate 9 (433 
g, 2.10 mol, purchased from Acros Organics) were mixed together in the presence of NaI (1.0 g, 
0.0067 mol, 0.4 mol %) in DMF (1 L). The mixture was heated to reflux for 2 hours, cooled and 
poured into ice water (500 mL).  A white precipitate formed and more ice was added until no 
additional precipitate formed. The sticky white precipitate was collected by vacuum filtration and 
allowed to dry in air for 30 minutes. The filter cake was dissolved in 50% ethanol-water (2000 
mL) and recrystallized to furnish 419 g of 3 as white crystals (72% yield), mp 204-207 °C. 1H 
NMR (400 MHz, DMSO) δ 4.54 (s, 2H), 6.73 (d, J = 8.8, 2H), 7.36 (d, J = 8.8, 2H), 8.00 (dt, J = 
6.8, 14.3, 2H), 8.11 (d, J = 7.5, 1H), 8.30 (d, J = 7.6, 1H), 9.26 (s, 1H), 10.07 (s, 1H). 13C NMR 
(DMSO) δ 41.2, 115.9, 121.8, 122.3, 125.8, 127.2, 130.8, 135.9, 136.5, 137.6, 154.4, 159.4, 
163.3. Anal. Calcd. for C15H12N2O5S: C, 54.21; H, 3.64; N, 8.43. Found: C, 54.15; H, 3.58; N, 
8.41. 
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SCP-123 (4). A suspension of SCP-1 (3, 50 g, 0.15 mol) and aqueous 0.5N NaOH (600 mL, 0.30 
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mol) was stirred at room temperature for 1 hour. Ethanol (400 mL) was added to the mixture 
until the solution become clear. Stirring was continued for an additional 1 hour. The solution was 
acidified with 2N HCl (500 mL) solution to a pH of 1 (pH meter). The white precipitate that 
formed was filtered and washed with distilled water (100 mL). The filter cake was dried under 
vacuum to afford 49 g of 4 as a white solid (93%, yield), mp 184-186 °C. 1H NMR (400 MHz, 
DMSO) δ 3.72 (d, J = 5.1, 2H), 6.65 (d, J = 8.8, 2H), 7.20 (d, J = 8.8, 2H), 7.39 (s, 1H), 
7.65-7.77 (m, 3H), 7.93 (m, 1H), 9.21 (s, 1H), 9.71 (s, 1H), 13.81 (b, 1H). 13C NMR (DMSO) δ 
46.5, 115.8, 121.7, 129.3, 130.4, 130.7, 131.7, 133.2, 133.4, 138.2, 154.2, 166.0, 169.5. Anal. 
Calcd. for C15H14N2O6S: C, 51.42; H, 4.03; N, 8.00. Found: C, 51.42; H, 4.15; N, 7.86. 
 
N
H
O
HN
S
CO2Na
OH
O O
 
SCP-123ss•H2O (5•H2O). The acid SCP-123 (4, 71.5 g, 0.24 mol) was suspended in ethanol 
(400 mL) and cooled in an ice bath. A pre-cooled (0 °C) solution of NaOH (8.2 g, 0.24 mol) in 
distilled water (40 mL) was added drop wise to the ethanolic suspension. After the addition of 
the basic solution was complete more ethanol was added to the mixture, if needed, to dissolve all 
the solids.  The clear reaction mixture was stirred for an additional 2 hours. The reaction 
mixture was then evaporated by 10% (~50 mL) on a rotoevaporator without a water bath. Once a 
precipitate started to form, the mixture was removed from the rotoevaporator and cooled in an 
ice bath for 1 hour. The white precipitate was filtered and washed with distilled water (100 mL). 
The filter cake was dried under vacuum at 60 °C to afford 93 g of 5•H2O as white solid (99% 
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yield). mp 188-190 °C. 1H NMR (400 MHz, DMSO) δ 3.57 (s, 2H), 6.65 (d, J = 8.8, 2H), 7.24 (d, 
J = 8.8, 2H), 7.39 (t, J = 7.0, 1H), 7.51 (t, J = 7.5, 1H), 7.63 (d, J = 6.6, 1H), 7.74 (d, J = 7.7, 1H), 
9.00 (s, 1H), 9.58 (s, 1H), 10.03 (s, 1H). 13C NMR (DMSO) δ 47.1, 115.7, 121.7, 128.0, 128.1, 
130.7, 130.8, 132.9, 136.3, 142.5, 154.3, 166.4, 171.3. Anal. Calcd. for C15H13N2NaO6S·H2O: C, 
46.15; H, 3.87; N, 7.18. Found: C, 46.01; H, 3.89; N, 7.14. 
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Saccharin sodium salt (9). The saccharin 13 (20.0 g, 109.2 mmol, 1.0 equiv) was dissolved in 
refluxing ethanol (120 mL). Another solution of sodium hydroxide (4.367 g, 109.2 mmol, 1.0 
equiv) in hot ethanol (50 mL) was added dropwise. The mixture was refluxed for 10 minutes, 
cooled to room temperature. And the precipitate was filtered and dried under vacuum to afford 
17.86 g (80% yield) of saccharin sodium salt (9) as a white solid, mp 355-357 oC. 1H NMR (400 
MHz, DMSO) δ 7.54-7.67 (m, 4H). 13C NMR (DMSO) δ 119.8, 123.2, 131.7, 132.3, 135.4, 
146.0, 168.7. Anal. Calcd. for C7H4NNaO3S: C, 40.98; H, 1.97; N, 6.83. Found: C, 41.05; H, 
1.90; N, 6.76. 
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2-[2,3-Dihydro-3-oxo-1,2-benzisothiazol-2-yl-1,1-dioxide]-acetic acid (11). 2-chloroacetic 
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acid (14) (4.725 g, 50 mmol, 1.0 equiv) and saccharin sodium salt (9) (16.46 g, 80 mmol, 1.6 
equiv) were mixed together in the presence of NaI (20 mg) in DMF (64 mL). The mixture was 
heated to reflux for 2 hours. The reaction was allowed to cool to room temperature, the 
precipitate was filtered and the filtrate was evaporated under reduced pressure. The residue was 
dissolved in EtOAc (200 mL), washed with brine (2 × 150 mL) and dried with Na2SO4. The 
solvent was removed under reduced pressure and the residue was recrystallized from EtOAc to 
afford 10.31 g (86% yield) of 11 as a white solid, mp 208-210 oC. 1H NMR (400 MHz, DMSO) δ 
4.47 (s, 2H), 7.98-8.14 (m, 3H), 8.33 (d, J = 7.6, 1H), 13.35 (s, 1H). 13C NMR (DMSO) δ 39.7, 
122.5, 125.9, 126.7, 136.1, 136.8, 137.7, 159.2, 168.2. Anal. Calcd. for C9H7NO5S: C, 44.81; H, 
2.92; N, 5.81. Found: C, 45.05; H, 2.88; N, 5.82. 
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[14C]-SCP-1 (16). A mixture of acetic acid (11) (358 mg, 1.48 mmol) and thionyl chloride (6 mL) 
was heated at reflux (external oil bath temperature of 85 oC) for 1.5 hours. The excess SOCl2 was 
removed under reduced pressure and the resulting acid chloride (1.48 mmol) was used without 
further purification in the subsequent reaction. The acid chloride (ca 1.48 mmol) was dissolved 
in dry THF (3 mL) and added dropwise over a period of 15 minutes to a mixture of 
4-aminophenol (119 mg, 1.09 mmol), 4-amino-[14C(U)]-phenol (2 mL, 1 mCi/mL, 77 mCi/mmol, 
in 0.01N HCl), NaOAc•3H2O (644 mg), HOAc (2.25 mL) and saturated NaOAc solution (0.9 
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mL) at -10 oC. After the addition, the reaction mixture was stirred at -10 oC for 1 hour and 
poured into icewater (65 g). The precipitate was collected by vacuum filtration and dried under 
vacuum overnight to furnish 249 mg (69% yield, specific activity: 1.09 mCi/mol) of [14C]-SCP-1 
(16) as a white solid. 1H NMR (400 MHz, DMSO) δ 4.50 (s, 2H), 6.69 (d, J = 8.9, 2H), 7.32 (d, J 
= 8.9, 2H), 8.00-8.15 (m, 3H), 8.33 (d, J = 7.4, 1H), 9.33 (s, 1H), 10.07 (s, 1H). 13C NMR 
(DMSO) δ 41.2, 115.8, 121.7, 122.4, 125.8, 127.1, 130.7, 136.0, 136.6, 137.6, 154.4, 159.4, 
163.2. 
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[14C]-SCP-123 (17). A mixture of [14C]-SCP-1 (16) (241 mg, 0.725 mmol) and aqueous 0.5N 
NaOH (2.9 mL) was stirred at room temperature for 1 hour. More ethanol was added to the 
mixture until the solution become clear. Keep stirring for an additional 1 hour. The solution was 
acidified with 2N HCl solution to PH = 1. Ethanol was removed as less as possible under 
reduced pressure. The resulting aqueous solution was extracted with EtOAc (2 × 15 mL). The 
combined extracts were washed with brine and dried over MgSO4. The solvent was removed 
under reduced pressure and the residue was triturated with hexanes. The resulting solid was 
recrystallized from ethyl acetate to afford 204 mg (80% yield, specific activity: 0.99 mCi/mol) of 
[14C]-SCP-123 (17) as a white solid. 1H NMR (400 MHz, DMSO) δ 3.70 (d, J = 5.0, 2H), 6.63 (d, 
J = 8.8, 2H), 7.19 (d, J = 8.9, 2H), 7.38 (s, 1H), 7.64-7.75 (m, 3H), 7.91 (m, 1H), 9.18 (s, 1H), 
9.69 (s, 1H), 13.74 (b, 1H). 13C NMR (DMSO) δ 46.5, 115.7, 121.6, 129.3, 130.4, 130.6, 131.6, 
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133.4, 138.2, 154.2, 165.9, 169.4. 
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p-Acetamidophenyl chloroacetate (18). Chloroacetyl chloride (0.2 mol, 22.6 g, 16 mL, 1.0 
equiv) was added to the solution of acetaminophen (1) (0.2 mol, 30.2 g, 1.0 equiv) in THF (120 
mL) in the presence of pyridine (0.2 mol, 15.82 g, 26.2 mL, 1.0 equiv). The mixture was kept 
stirring at room temperature for 2 hours, filtered, washed with water (50 mL). Recrystallization 
in ethanol afforded 36.2 g (80% yield) of p-acetamidophenyl chloroacetate (18) as white crystals, 
mp 187-189 oC. 1H NMR (400 MHz, DMSO) δ 2.03 (s, 3H), 4.65 (s, 2H), 7.08 (d, J = 8.8, 2H), 
7.60 (d, J = 8.8, 2H), 10.02 (s, 1H). Anal. Calcd. for C10H10ClNO3: C, 52.76; H, 4.43; N, 6.15. 
Found: C, 52.93; H, 4.45; N, 6.17. 
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Propacetamol hydrochloride (2). p-Acetamidophenyl chloroacetate (38) (0.03 mol, 7.6 g, 1.0 
equiv) was added in small portions to a solution of diethylamine (0.034 mol, 2.5 g, 3.54 mL, 1.13 
equiv) in triethylamine (10 mL) with stirring, while the temperature was maintained at 45 oC. 
The mixture was stirred for an additional 2 hours at 45 oC, cooled, poured into iced water (20 
mL), then extracted with ether (3 × 25 mL), dried over MgSO4 overnight and the ether was 
evaporated under vacuum to yield p-acetamidophenyl diethylamino acetate as an intermediate in 
the form of a thick oil. Hydrogenchloride gas was bubbled into the solution of the thick oil in dry 
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acetone (50 mL) at PH =1  to give white precipitate, washed with acetone and dried under 
vacuum to afford 4.1 g (41% yield) of propacetamol hydrochloride (2) as white solid mp 
210-212 oC. 1H NMR (400 MHz, DMSO) δ 1.25 (t, J = 7.2, 6H), 2.04 (s, 3H), 3.26 (d, J = 6.8, 
4H), 4.44 (s, 2H), 7.15 (d, J = 8.9, 2H), 7.66 (d, J = 8.9, 2H), 10.25 (s, 1H), 10.51 (b, 1H). Anal. 
Calcd. for C14H21ClN2O3: C, 55.90; H, 7.04; N, 9.31. Found: C, 55.63; H, 7.16; N, 9.06. 
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Expanded HNMR of (-)-1 + (+)-1 + BNPPA (1 equiv) 
 
 
 
Resolved HNMR signals  
Assigned Proton Chemical Shift Enantiomer 
H2´´ 9.11 (s) (-)-1 
H2´´ 9.08 (s) (+)-1 
H6eq 3.25 (d, J = 12 Hz) (+)-1 
H6eq 3.15(d, J = 12 Hz (-)-1 
H6ax 2.77 (dt, J = 12, 4 Hz) (+)-1 
H6ax 2.62 (dt, J = 12, 4 Hz) (-)-1 
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HNMR of (-)-1 + BNPPA (1 equiv) 
 
 
Enantiomer ratio (-)-1/(+)-1 was determined using the signal for H6ax = 13:1* (86% ee). 
*Integration was obtained using MestReNova® software. 
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HNMR of (+)-1 + BNPPA (1 equiv) 
 
 
 
 
Enantiomer ratio (-)-1/(+)-1 was determined using the signal for H2” = 9:1* (80 %ee). 
*Integration was obtained using MestReNova® software. 
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Crystal Structure of 
(1S,3aS)-1-(2-hydroxyethyl)-1,2,3,3a,4,5,8,9-octahydropyrrolo[1,2-a]quinolin-6(7H)-one (6)- 
Kishi’s intermediate 
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Table 1.  Crystal data and structure refinement for Kishi’s intermediate (6) 
 
Empirical formula  C14H21NO2 
Formula weight  235.32 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.83600(10) Å α= 90o. 
 b = 10.49690(10) Å β= 90o. 
 c = 13.3180(2) Å γ= 90o. 
Volume 1235.25(3) Å3 
Z 4 
Density (calculated) 1.265 Mg/m3 
Absorption coefficient 0.084 mm-1 
F(000) 512 
Crystal size 0.80 x 0.40 x 0.20 mm3 
Theta range for data collection 2.47 to 32.49o. 
Index ranges -13<=h<=13, -15<=k<=15, -20<=l<=20 
Reflections collected 52997 
Independent reflections 4454 [R(int) = 0.0208] 
Completeness to theta = 32.49o 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9834 and 0.9360 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4454 / 0 / 238 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0285, wR2 = 0.0805 
R indices (all data) R1 = 0.0291, wR2 = 0.0814 
Absolute structure parameter -0.4(6) 
Largest diff. peak and hole 0.371 and -0.182 e. Å-3 
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) 
for Kishi’s intermediate (6). U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
______________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________ 
N(1) 4153(1) 1342(1) 10115(1) 17(1) 
C(2) 3935(1) 2114(1) 9329(1) 15(1) 
C(3) 4005(1) 1532(1) 8296(1) 18(1) 
C(4) 3347(1) 2399(1) 7496(1) 22(1) 
C(5) 3991(1) 3732(1) 7589(1) 23(1) 
C(6) 3814(1) 4264(1) 8634(1) 19(1) 
O(7) 3770(1) 5442(1) 8756(1) 30(1) 
C(8) 3741(1) 3415(1) 9468(1) 17(1) 
C(9) 3499(1) 3977(1) 10499(1) 21(1) 
C(10) 3235(1) 2945(1) 11285(1) 23(1) 
C(11) 4368(1) 1876(1) 11127(1) 20(1) 
C(12) 4237(1) 717(1) 11810(1) 28(1) 
C(13) 4756(1) -383(1) 11141(1) 25(1) 
C(14) 4075(1) -59(1) 10114(1) 18(1) 
C(15) 2438(1) -520(1) 10005(1) 20(1) 
C(16) 2333(1) -1923(1) 9743(1) 25(1) 
O(17) 2895(1) -2090(1) 8753(1) 30(1) 
______________________________________________________________________ 
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Table 3. Bond lengths [Å] and angles [o] for Kishi’s intermediate (6). 
_____________________________________________________  
N(1)-C(2)  1.3386(8) 
N(1)-C(11)  1.4716(8) 
N(1)-C(14)  1.4719(8) 
C(2)-C(8)  1.3881(8) 
C(2)-C(3)  1.5069(8) 
C(3)-C(4)  1.5174(10) 
C(4)-C(5)  1.5161(11) 
C(5)-C(6)  1.5079(10) 
C(6)-O(7)  1.2480(8) 
C(6)-C(8)  1.4257(9) 
C(8)-C(9)  1.5093(9) 
C(9)-C(10)  1.5238(11) 
C(10)-C(11)  1.5185(10) 
C(11)-C(12)  1.5236(11) 
C(12)-C(13)  1.5287(12) 
C(13)-C(14)  1.5328(10) 
C(14)-C(15)  1.5323(9) 
C(15)-C(16)  1.5154(10) 
C(16)-O(17)  1.4202(10) 
 
C(2)-N(1)-C(11)        120.27(5) 
C(2)-N(1)-C(14) 126.66(6) 
C(11)-N(1)-C(14) 112.84(5) 
N(1)-C(2)-C(8) 120.59(6) 
N(1)-C(2)-C(3) 117.54(5) 
C(8)-C(2)-C(3) 121.75(5) 
C(2)-C(3)-C(4) 112.46(5) 
C(5)-C(4)-C(3) 110.61(6) 
C(6)-C(5)-C(4) 112.26(6) 
O(7)-C(6)-C(8) 121.18(7) 
O(7)-C(6)-C(5) 119.32(7) 
C(8)-C(6)-C(5) 119.48(6) 
C(2)-C(8)-C(6) 120.35(6) 
C(2)-C(8)-C(9) 121.56(6) 
 125
C(6)-C(8)-C(9) 118.06(6) 
C(8)-C(9)-C(10) 111.63(6) 
C(11)-C(10)-C(9) 109.21(6) 
N(1)-C(11)-C(10) 108.87(6) 
N(1)-C(11)-C(12) 103.45(6) 
C(10)-C(11)-C(12) 117.22(6) 
C(11)-C(12)-C(13) 103.40(6) 
C(12)-C(13)-C(14) 103.61(6) 
N(1)-C(14)-C(15) 111.12(5) 
N(1)-C(14)-C(13) 101.62(6) 
C(15)-C(14)-C(13) 112.63(6) 
C(16)-C(15)-C(14) 112.74(6) 
O(17)-C(16)-C(15) 108.17(6) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 4. Anisotropic displacement parameters (Å2 x 103) for Kishi’s intermediate (6). The 
anisotropic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h k a* b* U12 ] 
 
______________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________ 
N(1) 20(1)  16(1) 16(1)  0(1) 1(1)  -1(1) 
C(2) 14(1)  15(1) 16(1)  -1(1) 1(1)  -1(1) 
C(3) 22(1)  17(1) 16(1)  -3(1) 2(1)  -1(1) 
C(4) 25(1)  25(1) 16(1)  -1(1) 0(1)  -1(1) 
C(5) 28(1)  22(1) 21(1)  4(1) 4(1)  0(1) 
C(6) 17(1)  16(1) 25(1)  1(1) 3(1)  0(1) 
O(7) 33(1)  15(1) 42(1)  2(1) 5(1)  2(1) 
C(8) 16(1)  14(1) 19(1)  -2(1) 2(1)  -1(1) 
C(9) 23(1)  19(1) 22(1)  -7(1) 4(1)  0(1) 
C(10) 24(1)  27(1) 18(1)  -4(1) 4(1)  1(1) 
C(11) 19(1)  26(1) 16(1)  -1(1) 0(1)  -1(1) 
C(12) 30(1)  34(1) 19(1)  6(1) 0(1)  2(1) 
C(13) 22(1)  27(1) 27(1)  9(1) 0(1)  4(1) 
C(14) 17(1)  16(1) 23(1)  2(1) 4(1)  2(1) 
C(15) 17(1)  16(1) 28(1)  0(1) 4(1)  0(1) 
C(16) 31(1)  17(1) 28(1)  0(1) 8(1)  -3(1) 
O(17) 48(1)  18(1) 25(1)  0(1) 8(1)  2(1) 
______________________________________________________________________ 
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 
Kishi’s intermediate (6). 
 
______________________________________________________________________ 
 x  y  z  U(eq) 
______________________________________________________________________ 
  
H(3A) 5047(13) 1343(11) 8157(9) 21(3) 
H(3B) 3453(15) 673(14) 8274(10) 36(3) 
H(4A) 2260(16) 2424(13) 7558(9) 29(3) 
H(4B) 3589(15) 2044(12) 6844(9) 28(3) 
H(5A) 5042(16) 3695(13) 7403(10) 31(3) 
H(5B) 3483(18) 4322(16) 7074(12) 47(4) 
H(9A) 2623(15) 4558(13) 10474(9) 27(3) 
H(9B) 4380(16) 4526(14) 10678(10) 34(3) 
H(10A) 3306(17) 3293(14) 11959(11) 37(3) 
H(10B) 2229(15) 2564(13) 11225(9) 27(3) 
H(11) 5376(15) 2220(13) 11158(10) 31(3) 
H(12A) 3163(16) 623(13) 12017(10) 33(3) 
H(12B) 4827(18) 767(15) 12450(11) 43(4) 
H(13A) 5821(16) -366(13) 11117(10) 32(3) 
H(13B) 4379(16) -1255(13) 11387(10) 33(3) 
H(14) 4667(13) -394(12) 9554(9) 22(3) 
H(15A) 1885(14) -316(12) 10605(9) 25(3) 
H(15B) 1951(14) -30(12) 9475(9) 24(3) 
H(16A) 2888(15) -2455(14) 10195(9) 28(3) 
H(16B) 1311(16) -2197(13) 9780(10) 30(3) 
H(17) 3181(17) -2868(16) 8715(11) 41(4) 
______________________________________________________________________ 
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Table 6. Torsion angles [o] for Kishi’s intermediate (6). 
________________________________________________________________  
C(11)-N(1)-C(2)-C(8) -7.10(9) 
C(14)-N(1)-C(2)-C(8) 166.99(6) 
C(11)-N(1)-C(2)-C(3) 169.16(6) 
C(14)-N(1)-C(2)-C(3) -16.76(9) 
N(1)-C(2)-C(3)-C(4) 165.03(6) 
C(8)-C(2)-C(3)-C(4) -18.76(9) 
C(2)-C(3)-C(4)-C(5) 48.90(8) 
C(3)-C(4)-C(5)-C(6) -53.12(8) 
C(4)-C(5)-C(6)-O(7) -154.50(7) 
C(4)-C(5)-C(6)-C(8) 27.16(9) 
N(1)-C(2)-C(8)-C(6) 167.29(6) 
C(3)-C(2)-C(8)-C(6) -8.80(9) 
N(1)-C(2)-C(8)-C(9) -10.72(9) 
C(3)-C(2)-C(8)-C(9) 173.19(6) 
O(7)-C(6)-C(8)-C(2) -173.93(6) 
C(5)-C(6)-C(8)-C(2) 4.38(9) 
O(7)-C(6)-C(8)-C(9) 4.15(10) 
C(5)-C(6)-C(8)-C(9) -177.54(6) 
C(2)-C(8)-C(9)-C(10) -9.66(9) 
C(6)-C(8)-C(9)-C(10) 172.29(6) 
C(8)-C(9)-C(10)-C(11) 44.21(8) 
C(2)-N(1)-C(11)-C(10) 42.99(8) 
C(14)-N(1)-C(11)-C(10) -131.86(6) 
C(2)-N(1)-C(11)-C(12) 168.36(6) 
C(14)-N(1)-C(11)-C(12) -6.50(7) 
C(9)-C(10)-C(11)-N(1) -60.16(7) 
C(9)-C(10)-C(11)-C(12) -177.05(6) 
N(1)-C(11)-C(12)-C(13) 27.82(8) 
C(10)-C(11)-C(12)-C(13) 147.62(6) 
C(11)-C(12)-C(13)-C(14) -39.02(8) 
C(2)-N(1)-C(14)-C(15) -71.79(8) 
C(11)-N(1)-C(14)-C(15) 102.66(6) 
C(2)-N(1)-C(14)-C(13) 168.17(6) 
C(11)-N(1)-C(14)-C(13) -17.37(7) 
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C(12)-C(13)-C(14)-N(1) 34.11(7) 
C(12)-C(13)-C(14)-C(15) -84.86(7) 
N(1)-C(14)-C(15)-C(16) 165.84(6) 
C(13)-C(14)-C(15)-C(16) -80.89(7) 
C(14)-C(15)-C(16)-O(17) -68.29(8) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
H NMR Spectrum of SCP-123 (4) in DMSO-d6. 
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 1
H NMR Spectrum of SCP-123ss (5) in DMSO-d6. 
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 1
H NMR Spectrum of 12 in DMSO-d6. 
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 HPLC ANALYSIS 
 
1. REAGENTS AND INSTRUMENTATION 
-Trifluoroacetic acid, HPLC Grade Aldrich. 
      -Acetonitrile HPLC grade EM Science. 
-HPLC  Waters 501/486 Tunable Detector 
-Column: Waters Nova-Pak C18 (3.9 x 150 mm) Steel Analytical. 
 
2. CROMATOGRAPHIC CONDITIONS 
-Flow: 1.0 ml/min 
-Column Temperature 25
0
C 
-Volume injection: 5 l 
-Detector: Ultraviolet absorption- wavelength 254 nm. 
 
Mobile phase: Gradient, Table 1. 
A. TFA 0.1 % in acetonitrile 
B. TFA 0.1% in water. 
 
 
Table 1: Gradient. 
Time (min) %A %B 
0 0 100 
5 0 100 
30 100 0 
32 100 0 
33 0 100 
45 0 100 
 
 
3. RETENTION TIME 
 
Compound tR (min)* 
3 3.1 
4 15.8 
12 17.0 
*Average of three runs. 
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LC-ESI-MS IDENTIFICATION OF DIMER 12 
 
LC-TSQ Quantum Instrument (Thermo-Finnigan) coupled to Surveyor, equipped with 
electro-spray ionization (ESI) 
 
S
N
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CO2H
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H
N OH
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N
H
OO
HO2C
O
H
NHO
12
Chemical Formula: C30H26N4O12S2
MW: 698.68  
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